###begin article-title 0
Close association of water channel AQP1 with amyloid-beta deposition in Alzheimer disease brains
###end article-title 0
###begin p 1
###xml 1221 1225 1209 1213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
###xml 1093 1098 <span type="species:ncbi:9606">human</span>
Aquaporin-1 (AQP1), a membrane water channel protein, is expressed exclusively in the choroid plexus epithelium in the central nervous system under physiological conditions. However, AQP1 expression is enhanced in reactive astrocytes, accumulating in brain lesions of Creutzfeldt-Jakob disease and multiple sclerosis, suggesting a role of AQP1-expressing astrocytes in brain water homeostasis under pathological conditions. To clarify a pathological implication of AQP1 in Alzheimer disease (AD), we investigated the possible relationship between amyloid-beta (Abeta) deposition and astrocytic AQP1 expression in the motor cortex and hippocampus of 11 AD patients and 16 age-matched other neurological disease cases. In all cases, AQP1 was expressed exclusively in a subpopulation of multipolar fibrillary astrocytes. The great majority of AQP1-expressing astrocytes were located either on the top of or in close proximity to Abeta plaques in AD brains but not in non-AD cases, whereas those independent of Abeta deposition were found predominantly in non-AD brains. By Western blot, cultured human astrocytes constitutively expressed AQP1, and the levels of AQP1 protein expression were not affected by exposure to Abeta1-42 peptide, but were elevated by hypertonic sodium chloride. By immunoprecipitation, the C-terminal fragment-beta (CTFbeta) of amyloid precursor protein interacted with the N-terminal half of AQP1 spanning the transmembrane helices H1, H2 and H3. These observations suggest the possible association of astrocytic AQP1 with Abeta deposition in AD brains.
###end p 1
###begin title 2
Electronic supplementary material
###end title 2
###begin p 3
The online version of this article (doi:10.1007/s00401-008-0387-x) contains supplementary material, which is available to authorized users.
###end p 3
###begin title 4
Keywords
###end title 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 730 731 730 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1065 1067 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1119 1121 1119 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 1371 1373 1371 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1375 1377 1375 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1515 1517 1515 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 1730 1732 1730 1732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1390 1394 <span type="species:ncbi:10090">mice</span>
The aquaporins (AQPs) constitute a family of integral channel proteins that facilitate the osmotically driven bidirectional water transport across the cell membrane [2, 54]. Previous studies identified at least 13 mammalian members, widely expressed in various fluid-transporting epithelial and endothelial cells. AQP1, AQP2, AQP4, AQP5 and AQP8 are chiefly water selective, while AQP3, AQP7, AQP9 and AQP10 transport glycerol in addition to water. Among AQP family members, AQP1, AQP4 and AQP9 are expressed in the central nervous system (CNS) [2, 54]. AQP1, initially identified in red blood cells and renal proximal tubular epithelium, is expressed constitutively in the apical surface of choroid plexus epithelium in the CNS [8, 39]. The crystal structure of AQP1 water channel is composed of a dumbbell-shaped homotetramer of 28-kDa subunits, each of which contains six transmembrane domains and an extracellular epitope that defines the Colton blood group antigen on erythrocyte membranes [10]. Outside the brain, AQP1 is expressed in retinal amacrine cells [24], Schwann cells [14], dorsal root ganglia neurons [48], lungs and hepatobiliary epithelium. AQP1-null individuals negative for the Colton antigen, having homozygous mutations in the AQP1 gene exhibit a defect in urinary concentration and reduced pulmonary vascular permeability after overloading fluid [27, 28]. AQP1-null mice show a decrease in cerebrospinal fluid (CSF) production, indicating a pivotal role of AQP1 in CSF secretion in the CNS [42]. Although AQP1 is expressed widely in vascular endothelial cells outside the CNS, the levels of AQP1 expression are very low in brain endothelial cells, and no expression is found in cultured rodent astrocytes [12].
###end p 6
###begin p 7
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 869 871 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 964 966 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 447 452 <span type="species:ncbi:10090">Mouse</span>
Earlier studies showed that high-grade astrocytoma cells intensely express both AQP1 and AQP4, suggesting the involvement of water channel upregulation in development of tumor-associated brain edema [41, 45]. AQP1-null mice show a reduction in tumor vascularity and migratory capacity [46]. In contrast, overexpression of AQP1 in fibroblast in culture accelerates anchorage-independent cell growth characteristic of malignant transformation [19]. Mouse melanoma cells, overexpressing AQP1 show an increase in metastatic potential [21]. AQP1 plays a central role in macrophage and leukocyte recruitment during acute inflammation [40]. Based on these observations, it is proposed that AQP1 regulates cell growth and migration by a mechanism that involves cytoskeletal reorganization, triggered by water transport at the leading edge of proliferating and migrating cells [54]. Furthermore, AQP1 plays a role in apoptotic cell shrinkage by regulating the cell volume [22].
###end p 7
###begin p 8
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">51</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 804 806 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 888 890 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 892 894 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">55</xref>
Increasing evidence indicates that astrocytes express AQP1 in CNS under pathological conditions. The expression of both AQP1 and AQP4 is enhanced markedly in reactive astrocytes accumulating in the lesions of subarachnoid hemorrhage [4], contusion [51], Creutzfeldt-Jakob disease (CJD) [44], cerebral infarction [47], and multiple sclerosis (MS) [47]. However, the precise mechanism accounting for upregulation of AQP1 in reactive astrocytes remains unknown. A recent study showed that the expression of AQP1 but not that of AQP4 is augmented in cortical astrocytes at the early stage of Alzheimer disease (AD), suggesting a pathological role of abnormal regulation of water transport in AD [43]. Because intracerebral accumulation of amyloid-beta (Abeta) plays a central role in the pathogenesis of AD [16], and activated astrocytes are often associated with Abeta plaques in AD brains [37, 55], we investigated the possible relationship between Abeta deposition and AQP1 expression in astrocytes in the cerebral cortex of AD.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human brain tissues
###end title 10
###begin p 11
###xml 271 274 269 270 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#177;</bold>
###xml 1120 1122 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 1259 1260 1251 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 104 107 <span type="species:ncbi:9606">men</span>
###xml 116 121 <span type="species:ncbi:9606">women</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 227 230 <span type="species:ncbi:9606">men</span>
###xml 241 246 <span type="species:ncbi:9606">women</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
Ten micron-thick serial sections were prepared from autopsied brains of 11 AD patients composed of five men and six women with the mean age of 71 +/- 9 years and 16 other neurological disease (non-AD) patients composed of nine men and seven women with the mean age of 67 +/- 12 years. The non-AD cases include three patients with Parkinson disease (PD), three with multiple system atrophy (MSA), four with amyotrophic lateral sclerosis (ALS), three with myotonic dystrophy, one with spinal and bulbar muscular atrophy (SBMA), one with schizophrenia, and one with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). The average of brain weight was 1,038 +/- 163 g in AD cases and 1,220 +/- 173 g in non-AD cases. Brain tissues of the motor cortex and hippocampus were fixed with 4% paraformaldehyde (PFA) and embedded in paraffin. In the present study, we tentatively defined the hippocampus and parahippocampal cortex as the hippocampus. All AD cases were satisfied with the Consortium to Establish a Registry for Alzheimer's disease (CERAD) criteria for diagnosis of definite AD [34]. They were categorized into stage C of amyloid deposition and stage VI of neurofibrillary degeneration, following the Braak's staging [9]. The autopsied brain samples were obtained from Research Resource Network (RRN), Japan. Written informed consent was obtained from all the cases examined. The Ethics Committee of National Center of Neurology and Psychiatry approved the present study.
###end p 11
###begin title 12
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human astrocytes in culture
###end title 12
###begin p 13
###xml 1005 1007 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 367 372 <span type="species:ncbi:9606">human</span>
###xml 422 427 <span type="species:ncbi:9606">human</span>
###xml 486 491 <span type="species:ncbi:9606">human</span>
###xml 666 672 <span type="species:ncbi:9913">bovine</span>
Human astrocytes were established from neuronal progenitor (NP) cells isolated from a human fetal brain (BioWhittaker-Cambrex, Walkersville, MD, USA). NP cells plated on a polyethyleneimine-coated surface were incubated in DMEM/F-12 medium (Invitrogen, Carlsbad, CA, USA) containing an insulin-transferrin-selenium (ITS) supplement (Invitrogen), 20 ng/ml recombinant human EGF (Higeta, Tokyo, Japan), 20 ng/ml recombinant human bFGF (PeproTech EC, London, UK), and 10 ng/ml recombinant human LIF (Chemicon, Temecula, CA, USA). For the induction of astrocyte differentiation, NP cells were incubated for several weeks in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mug/ml streptomycin (feeding medium). The inclusion of FBS in the culture medium induced vigorous proliferation and differentiation of astrocytes accompanied by a rapid reduction in non-astroglial cells. The purity of astrocytes exceeded 98% by GFAP immunolabeling, as described previously [47].
###end p 13
###begin p 14
###xml 171 175 167 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-40</sub>
###xml 237 241 229 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 371 380 361 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">all trans</italic>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 226 231 <span type="species:ncbi:9606">human</span>
To determine the effects of stress-inducing stimuli on AQP1 expression, human astrocytes were incubated for 48 h in the feeding medium with inclusion of 10 muM human Abeta1-40 peptide (Peptide Institute, Osaka, Japan), 10 muM human Abeta1-42 peptide (Peptide Institute), 100 mM NaCl, 100 muM sodium nitroprusside, a NO donor (SNP; Merck-Calbiochem, Tokyo, Japan), 10 muM all trans retinoic acid (RA; Sigma, St Louis, MO, USA), 100 nM phorbol 12-myristate 13-acetate (PMA; Sigma), 1 mM dibutyryl cyclic AMP (dbcAMP; Sigma), 10 muM MG-132, a proteasome inhibitor (Merck-Calbiochem), or 1 muM thapsigargin, an endoplasmic reticulum (ER) stress inducer (TG; Sigma), or incubated in the serum-free DMEM/F-12 medium containing 100 muM hydrogen peroxide.
###end p 14
###begin title 15
Double-labeling immunohistochemistry
###end title 15
###begin p 16
###xml 573 574 558 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 990 992 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 1535 1536 1514 1515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1789 1796 1768 1775 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1796 1869 1775 1848 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Primary antibodies utilized for immunochemistry and Western blot analysis</p>
###xml 1796 1869 1775 1848 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Primary antibodies utilized for immunochemistry and Western blot analysis</p></caption>
###xml 1869 1886 1848 1865 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Antibodies (Name)</th>
###xml 1886 1895 1865 1874 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Suppliers</th>
###xml 1895 1899 1874 1878 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Code</th>
###xml 1899 1905 1878 1884 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Origin</th>
###xml 1905 1915 1884 1894 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Immunogens</th>
###xml 1915 1934 1894 1913 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Antigen specificity</th>
###xml 1934 1977 1913 1956 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Concentration used for immunohistochemistry</th>
###xml 1977 2016 1956 1995 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Concentration used for Western blotting</th>
###xml 1869 2016 1848 1995 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Antibodies (Name)</th><th align="left">Suppliers</th><th align="left">Code</th><th align="left">Origin</th><th align="left">Immunogens</th><th align="left">Antigen specificity</th><th align="left">Concentration used for immunohistochemistry</th><th align="left">Concentration used for Western blotting</th></tr>
###xml 1869 2016 1848 1995 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Antibodies (Name)</th><th align="left">Suppliers</th><th align="left">Code</th><th align="left">Origin</th><th align="left">Immunogens</th><th align="left">Antigen specificity</th><th align="left">Concentration used for immunohistochemistry</th><th align="left">Concentration used for Western blotting</th></tr></thead>
###xml 2016 2027 1995 2006 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AQP1 (H-55)</td>
###xml 2027 2051 2006 2030 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Santa Cruz Biotechnology</td>
###xml 2051 2059 2030 2038 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">sc-20810</td>
###xml 2059 2065 2038 2044 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Rabbit</td>
###xml 2065 2125 2044 2104 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A peptide covering amino acid residues 215&#8211;269 of human AQP1</td>
###xml 2125 2129 2104 2108 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AQP1</td>
###xml 2129 2138 2108 2117 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">800&#160;ng/ml</td>
###xml 2138 2147 2117 2126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">200&#160;ng/ml</td>
###xml 2016 2147 1995 2126 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AQP1 (H-55)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-20810</td><td align="left">Rabbit</td><td align="left">A peptide covering amino acid residues 215&#8211;269 of human AQP1</td><td align="left">AQP1</td><td align="left">800&#160;ng/ml</td><td align="left">200&#160;ng/ml</td></tr>
###xml 2147 2158 2126 2137 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AQP1 (1/22)</td>
###xml 2158 2182 2137 2161 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Santa Cruz Biotechnology</td>
###xml 2182 2190 2161 2169 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">sc-32727</td>
###xml 2190 2195 2169 2174 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mouse</td>
###xml 2195 2253 2174 2232 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A peptide covering amino acid residues 249&#8211;269 of rat AQP1</td>
###xml 2253 2257 2232 2236 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AQP1</td>
###xml 2257 2265 2236 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4&#160;&#956;g/ml</td>
###xml 2265 2267 2243 2245 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 2147 2267 2126 2245 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AQP1 (1/22)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-32727</td><td align="left">Mouse</td><td align="left">A peptide covering amino acid residues 249&#8211;269 of rat AQP1</td><td align="left">AQP1</td><td align="left">4&#160;&#956;g/ml</td><td align="left">NA</td></tr>
###xml 2267 2278 2245 2256 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AQP4 (H-80)</td>
###xml 2278 2302 2256 2280 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Santa Cruz Biotechnology</td>
###xml 2302 2310 2280 2288 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">sc-20812</td>
###xml 2310 2316 2288 2294 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Rabbit</td>
###xml 2316 2402 2294 2380 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A peptide covering amino acid residues 244&#8211;323 mapping at the C-terminus of human AQP4</td>
###xml 2402 2406 2380 2384 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AQP4</td>
###xml 2406 2415 2384 2393 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">800&#160;ng/ml</td>
###xml 2415 2417 2393 2395 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 2267 2417 2245 2395 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AQP4 (H-80)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-20812</td><td align="left">Rabbit</td><td align="left">A peptide covering amino acid residues 244&#8211;323 mapping at the C-terminus of human AQP4</td><td align="left">AQP4</td><td align="left">800&#160;ng/ml</td><td align="left">NA</td></tr>
###xml 2422 2427 2397 2402 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11-28</sub>
###xml 2417 2434 2395 2409 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A&#946;<sub>11-28</sub> (12B2)</td>
###xml 2434 2461 2409 2436 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Immunobiological Laboratory</td>
###xml 2461 2466 2436 2441 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10027</td>
###xml 2466 2471 2441 2446 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mouse</td>
###xml 2471 2503 2446 2478 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human amyloid beta 11&#8211;28 peptide</td>
###xml 2508 2512 2480 2484 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-40</sub>
###xml 2519 2523 2488 2492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 2530 2534 2496 2500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-43</sub>
###xml 2503 2534 2478 2500 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A&#946;<sub>1-40</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>1-43</sub></td>
###xml 2534 2542 2500 2507 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1&#160;&#956;g/ml</td>
###xml 2542 2544 2507 2509 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 2417 2544 2395 2509 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">A&#946;<sub>11-28</sub> (12B2)</td><td align="left">Immunobiological Laboratory</td><td align="left">10027</td><td align="left">Mouse</td><td align="left">Human amyloid beta 11&#8211;28 peptide</td><td align="left">A&#946;<sub>1-40</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>1-43</sub></td><td align="left">1&#160;&#956;g/ml</td><td align="left">NA</td></tr>
###xml 2544 2554 2509 2519 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GFAP (GA5)</td>
###xml 2554 2562 2519 2527 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Nichirei</td>
###xml 2562 2568 2527 2533 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">422261</td>
###xml 2568 2573 2533 2538 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mouse</td>
###xml 2573 2604 2538 2569 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Purified swine spinal cord GFAP</td>
###xml 2604 2608 2569 2573 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GFAP</td>
###xml 2608 2618 2573 2583 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Prediluted</td>
###xml 2618 2620 2583 2585 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 2544 2620 2509 2585 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GFAP (GA5)</td><td align="left">Nichirei</td><td align="left">422261</td><td align="left">Mouse</td><td align="left">Purified swine spinal cord GFAP</td><td align="left">GFAP</td><td align="left">Prediluted</td><td align="left">NA</td></tr>
###xml 2620 2630 2585 2595 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD68 (KP1)</td>
###xml 2630 2634 2595 2599 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Dako</td>
###xml 2634 2639 2599 2604 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">N1577</td>
###xml 2639 2644 2604 2609 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mouse</td>
###xml 2644 2688 2609 2653 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Lysosomal granules of human lung macrophages</td>
###xml 2688 2692 2653 2657 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CD68</td>
###xml 2692 2702 2657 2667 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Prediluted</td>
###xml 2702 2704 2667 2669 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 2620 2704 2585 2669 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">CD68 (KP1)</td><td align="left">Dako</td><td align="left">N1577</td><td align="left">Mouse</td><td align="left">Lysosomal granules of human lung macrophages</td><td align="left">CD68</td><td align="left">Prediluted</td><td align="left">NA</td></tr>
###xml 2704 2723 2669 2688 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Factor VIII (F8/86)</td>
###xml 2723 2731 2688 2696 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Nichirei</td>
###xml 2731 2737 2696 2702 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">412191</td>
###xml 2737 2742 2702 2707 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mouse</td>
###xml 2742 2775 2707 2740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human factor VIII-related antigen</td>
###xml 2775 2802 2740 2767 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Factor VIII-related antigen</td>
###xml 2802 2812 2767 2777 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Prediluted</td>
###xml 2812 2814 2777 2779 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 2704 2814 2669 2779 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Factor VIII (F8/86)</td><td align="left">Nichirei</td><td align="left">412191</td><td align="left">Mouse</td><td align="left">Human factor VIII-related antigen</td><td align="left">Factor VIII-related antigen</td><td align="left">Prediluted</td><td align="left">NA</td></tr>
###xml 2814 2817 2779 2782 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NSE</td>
###xml 2817 2825 2782 2790 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Nichirei</td>
###xml 2825 2831 2790 2796 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">422081</td>
###xml 2831 2837 2796 2802 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Rabbit</td>
###xml 2837 2862 2802 2827 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Purified bovine brain NSE</td>
###xml 2862 2865 2827 2830 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NSE</td>
###xml 2865 2875 2830 2840 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Prediluted</td>
###xml 2875 2877 2840 2842 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 2814 2877 2779 2842 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">NSE</td><td align="left">Nichirei</td><td align="left">422081</td><td align="left">Rabbit</td><td align="left">Purified bovine brain NSE</td><td align="left">NSE</td><td align="left">Prediluted</td><td align="left">NA</td></tr>
###xml 2877 2889 2842 2854 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ACTB (AC-15)</td>
###xml 2889 2894 2854 2859 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sigma</td>
###xml 2894 2899 2859 2864 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A1978</td>
###xml 2899 2904 2864 2869 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mouse</td>
###xml 2904 2962 2869 2927 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A synthetic peptide mimicking the N-terminus of beta-actin</td>
###xml 2962 2972 2927 2937 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">beta-Actin</td>
###xml 2972 2974 2937 2939 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NA</td>
###xml 2974 2983 2939 2948 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">500&#160;ng/ml</td>
###xml 2877 2983 2842 2948 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ACTB (AC-15)</td><td align="left">Sigma</td><td align="left">A1978</td><td align="left">Mouse</td><td align="left">A synthetic peptide mimicking the N-terminus of beta-actin</td><td align="left">beta-Actin</td><td align="left">NA</td><td align="left">500&#160;ng/ml</td></tr>
###xml 2983 2989 2948 2954 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Xpress</td>
###xml 2989 2999 2954 2964 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Invitrogen</td>
###xml 2999 3006 2964 2971 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">R910-25</td>
###xml 3006 3011 2971 2976 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mouse</td>
###xml 3011 3034 2976 2999 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Xpress epitope sequence</td>
###xml 3034 3040 2999 3005 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Xpress</td>
###xml 3040 3048 3005 3012 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6&#160;&#956;g/ml</td>
###xml 3048 3057 3012 3021 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">240&#160;ng/ml</td>
###xml 2983 3057 2948 3021 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Xpress</td><td align="left">Invitrogen</td><td align="left">R910-25</td><td align="left">Mouse</td><td align="left">Xpress epitope sequence</td><td align="left">Xpress</td><td align="left">6&#160;&#956;g/ml</td><td align="left">240&#160;ng/ml</td></tr>
###xml 2016 3057 1995 3021 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">AQP1 (H-55)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-20810</td><td align="left">Rabbit</td><td align="left">A peptide covering amino acid residues 215&#8211;269 of human AQP1</td><td align="left">AQP1</td><td align="left">800&#160;ng/ml</td><td align="left">200&#160;ng/ml</td></tr><tr><td align="left">AQP1 (1/22)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-32727</td><td align="left">Mouse</td><td align="left">A peptide covering amino acid residues 249&#8211;269 of rat AQP1</td><td align="left">AQP1</td><td align="left">4&#160;&#956;g/ml</td><td align="left">NA</td></tr><tr><td align="left">AQP4 (H-80)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-20812</td><td align="left">Rabbit</td><td align="left">A peptide covering amino acid residues 244&#8211;323 mapping at the C-terminus of human AQP4</td><td align="left">AQP4</td><td align="left">800&#160;ng/ml</td><td align="left">NA</td></tr><tr><td align="left">A&#946;<sub>11-28</sub> (12B2)</td><td align="left">Immunobiological Laboratory</td><td align="left">10027</td><td align="left">Mouse</td><td align="left">Human amyloid beta 11&#8211;28 peptide</td><td align="left">A&#946;<sub>1-40</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>1-43</sub></td><td align="left">1&#160;&#956;g/ml</td><td align="left">NA</td></tr><tr><td align="left">GFAP (GA5)</td><td align="left">Nichirei</td><td align="left">422261</td><td align="left">Mouse</td><td align="left">Purified swine spinal cord GFAP</td><td align="left">GFAP</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">CD68 (KP1)</td><td align="left">Dako</td><td align="left">N1577</td><td align="left">Mouse</td><td align="left">Lysosomal granules of human lung macrophages</td><td align="left">CD68</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">Factor VIII (F8/86)</td><td align="left">Nichirei</td><td align="left">412191</td><td align="left">Mouse</td><td align="left">Human factor VIII-related antigen</td><td align="left">Factor VIII-related antigen</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">NSE</td><td align="left">Nichirei</td><td align="left">422081</td><td align="left">Rabbit</td><td align="left">Purified bovine brain NSE</td><td align="left">NSE</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">ACTB (AC-15)</td><td align="left">Sigma</td><td align="left">A1978</td><td align="left">Mouse</td><td align="left">A synthetic peptide mimicking the N-terminus of beta-actin</td><td align="left">beta-Actin</td><td align="left">NA</td><td align="left">500&#160;ng/ml</td></tr><tr><td align="left">Xpress</td><td align="left">Invitrogen</td><td align="left">R910-25</td><td align="left">Mouse</td><td align="left">Xpress epitope sequence</td><td align="left">Xpress</td><td align="left">6&#160;&#956;g/ml</td><td align="left">240&#160;ng/ml</td></tr></tbody>
###xml 1869 3057 1848 3021 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Antibodies (Name)</th><th align="left">Suppliers</th><th align="left">Code</th><th align="left">Origin</th><th align="left">Immunogens</th><th align="left">Antigen specificity</th><th align="left">Concentration used for immunohistochemistry</th><th align="left">Concentration used for Western blotting</th></tr></thead><tbody><tr><td align="left">AQP1 (H-55)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-20810</td><td align="left">Rabbit</td><td align="left">A peptide covering amino acid residues 215&#8211;269 of human AQP1</td><td align="left">AQP1</td><td align="left">800&#160;ng/ml</td><td align="left">200&#160;ng/ml</td></tr><tr><td align="left">AQP1 (1/22)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-32727</td><td align="left">Mouse</td><td align="left">A peptide covering amino acid residues 249&#8211;269 of rat AQP1</td><td align="left">AQP1</td><td align="left">4&#160;&#956;g/ml</td><td align="left">NA</td></tr><tr><td align="left">AQP4 (H-80)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-20812</td><td align="left">Rabbit</td><td align="left">A peptide covering amino acid residues 244&#8211;323 mapping at the C-terminus of human AQP4</td><td align="left">AQP4</td><td align="left">800&#160;ng/ml</td><td align="left">NA</td></tr><tr><td align="left">A&#946;<sub>11-28</sub> (12B2)</td><td align="left">Immunobiological Laboratory</td><td align="left">10027</td><td align="left">Mouse</td><td align="left">Human amyloid beta 11&#8211;28 peptide</td><td align="left">A&#946;<sub>1-40</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>1-43</sub></td><td align="left">1&#160;&#956;g/ml</td><td align="left">NA</td></tr><tr><td align="left">GFAP (GA5)</td><td align="left">Nichirei</td><td align="left">422261</td><td align="left">Mouse</td><td align="left">Purified swine spinal cord GFAP</td><td align="left">GFAP</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">CD68 (KP1)</td><td align="left">Dako</td><td align="left">N1577</td><td align="left">Mouse</td><td align="left">Lysosomal granules of human lung macrophages</td><td align="left">CD68</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">Factor VIII (F8/86)</td><td align="left">Nichirei</td><td align="left">412191</td><td align="left">Mouse</td><td align="left">Human factor VIII-related antigen</td><td align="left">Factor VIII-related antigen</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">NSE</td><td align="left">Nichirei</td><td align="left">422081</td><td align="left">Rabbit</td><td align="left">Purified bovine brain NSE</td><td align="left">NSE</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">ACTB (AC-15)</td><td align="left">Sigma</td><td align="left">A1978</td><td align="left">Mouse</td><td align="left">A synthetic peptide mimicking the N-terminus of beta-actin</td><td align="left">beta-Actin</td><td align="left">NA</td><td align="left">500&#160;ng/ml</td></tr><tr><td align="left">Xpress</td><td align="left">Invitrogen</td><td align="left">R910-25</td><td align="left">Mouse</td><td align="left">Xpress epitope sequence</td><td align="left">Xpress</td><td align="left">6&#160;&#956;g/ml</td><td align="left">240&#160;ng/ml</td></tr></tbody></table>
###xml 3057 3061 3021 3025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AQP1</italic>
###xml 3075 3079 3039 3043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AQP4</italic>
###xml 3093 3098 3057 3059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
###xml 3113 3117 3074 3078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFAP</italic>
###xml 3151 3154 3112 3115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NSE</italic>
###xml 3180 3184 3141 3145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 3197 3199 3158 3160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
###xml 3057 3211 3021 3172 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><italic>AQP1</italic> aquaporin-1, <italic>AQP4</italic> aquaporin-4, <italic>A&#946;</italic> amyloid-beta, <italic>GFAP</italic> glial fibrillary acidic protein, <italic>NSE</italic> neuron-specific enolase, <italic>ACTB</italic> beta-actin, <italic>NA</italic> not applied</p>
###xml 3057 3211 3021 3172 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18"><italic>AQP1</italic> aquaporin-1, <italic>AQP4</italic> aquaporin-4, <italic>A&#946;</italic> amyloid-beta, <italic>GFAP</italic> glial fibrillary acidic protein, <italic>NSE</italic> neuron-specific enolase, <italic>ACTB</italic> beta-actin, <italic>NA</italic> not applied</p></table-wrap-foot>
###xml 1789 3211 1768 3172 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="17">Primary antibodies utilized for immunochemistry and Western blot analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Antibodies (Name)</th><th align="left">Suppliers</th><th align="left">Code</th><th align="left">Origin</th><th align="left">Immunogens</th><th align="left">Antigen specificity</th><th align="left">Concentration used for immunohistochemistry</th><th align="left">Concentration used for Western blotting</th></tr></thead><tbody><tr><td align="left">AQP1 (H-55)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-20810</td><td align="left">Rabbit</td><td align="left">A peptide covering amino acid residues 215&#8211;269 of human AQP1</td><td align="left">AQP1</td><td align="left">800&#160;ng/ml</td><td align="left">200&#160;ng/ml</td></tr><tr><td align="left">AQP1 (1/22)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-32727</td><td align="left">Mouse</td><td align="left">A peptide covering amino acid residues 249&#8211;269 of rat AQP1</td><td align="left">AQP1</td><td align="left">4&#160;&#956;g/ml</td><td align="left">NA</td></tr><tr><td align="left">AQP4 (H-80)</td><td align="left">Santa Cruz Biotechnology</td><td align="left">sc-20812</td><td align="left">Rabbit</td><td align="left">A peptide covering amino acid residues 244&#8211;323 mapping at the C-terminus of human AQP4</td><td align="left">AQP4</td><td align="left">800&#160;ng/ml</td><td align="left">NA</td></tr><tr><td align="left">A&#946;<sub>11-28</sub> (12B2)</td><td align="left">Immunobiological Laboratory</td><td align="left">10027</td><td align="left">Mouse</td><td align="left">Human amyloid beta 11&#8211;28 peptide</td><td align="left">A&#946;<sub>1-40</sub>, A&#946;<sub>1-42</sub>, A&#946;<sub>1-43</sub></td><td align="left">1&#160;&#956;g/ml</td><td align="left">NA</td></tr><tr><td align="left">GFAP (GA5)</td><td align="left">Nichirei</td><td align="left">422261</td><td align="left">Mouse</td><td align="left">Purified swine spinal cord GFAP</td><td align="left">GFAP</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">CD68 (KP1)</td><td align="left">Dako</td><td align="left">N1577</td><td align="left">Mouse</td><td align="left">Lysosomal granules of human lung macrophages</td><td align="left">CD68</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">Factor VIII (F8/86)</td><td align="left">Nichirei</td><td align="left">412191</td><td align="left">Mouse</td><td align="left">Human factor VIII-related antigen</td><td align="left">Factor VIII-related antigen</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">NSE</td><td align="left">Nichirei</td><td align="left">422081</td><td align="left">Rabbit</td><td align="left">Purified bovine brain NSE</td><td align="left">NSE</td><td align="left">Prediluted</td><td align="left">NA</td></tr><tr><td align="left">ACTB (AC-15)</td><td align="left">Sigma</td><td align="left">A1978</td><td align="left">Mouse</td><td align="left">A synthetic peptide mimicking the N-terminus of beta-actin</td><td align="left">beta-Actin</td><td align="left">NA</td><td align="left">500&#160;ng/ml</td></tr><tr><td align="left">Xpress</td><td align="left">Invitrogen</td><td align="left">R910-25</td><td align="left">Mouse</td><td align="left">Xpress epitope sequence</td><td align="left">Xpress</td><td align="left">6&#160;&#956;g/ml</td><td align="left">240&#160;ng/ml</td></tr></tbody></table><table-wrap-foot><p textid="18"><italic>AQP1</italic> aquaporin-1, <italic>AQP4</italic> aquaporin-4, <italic>A&#946;</italic> amyloid-beta, <italic>GFAP</italic> glial fibrillary acidic protein, <italic>NSE</italic> neuron-specific enolase, <italic>ACTB</italic> beta-actin, <italic>NA</italic> not applied</p></table-wrap-foot></table-wrap>
###xml 399 403 <span type="species:ncbi:9925">goat</span>
###xml 946 951 <span type="species:ncbi:9606">human</span>
###xml 1566 1577 <span type="species:ncbi:3704">horseradish</span>
###xml 2115 2120 <span type="species:ncbi:9606">human</span>
###xml 2245 2248 <span type="species:ncbi:10116">rat</span>
###xml 2392 2397 <span type="species:ncbi:9606">human</span>
###xml 2582 2587 <span type="species:ncbi:9823">swine</span>
###xml 2666 2671 <span type="species:ncbi:9606">human</span>
###xml 2846 2852 <span type="species:ncbi:9913">bovine</span>
After deparaffination, tissue sections were heated in 10 mM citrate sodium buffer, pH 6.0 by autoclave at 125degreesC for 30 s in a temperature-controlled pressure chamber (Dako, Tokyo, Japan). For Abeta immunolabeling, tissue sections were pretreated with formic acid for 5 min at room temperature (RT). All tissue sections were incubated with phosphate-buffered saline (PBS) containing 10% normal goat serum (NGS) at RT for 15 min to block non-specific staining. Then, tissue sections were initially stained at 4degreesC overnight with primary antibodies listed in Table 1, followed by incubation with alkaline phosphatase (AP)-conjugated secondary antibody (Nichirei), and colorized with New Fuchsin substrate. The specificity of anti-AQP1 antibody (H-55, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-AQP4 antibody (H-80, Santa Cruz Biotechnology) was verified by Western blot analysis of HEK293 cells that express the transgene of human AQP1 or AQP4 as described previously [47]. In addition, we found that choroid plexus epithelial cells, representing a positive control cell type, were stained intensely by H-55 (Supplementary Fig. 1). After inactivation of the antibody by autoclaving the sections at 125degreesC for 30 s in 10 mM citrate sodium buffer, pH 6.0 following the manufacturer's instruction (Nichirei), they were treated for 15 min with 3% hydrogen peroxide-containing distilled water to block the endogenous peroxidase activity. Then, they were relabeled with different primary antibodies listed in Table 1, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibody (Nichirei), and colorized with DAB substrate and counterstained with hematoxylin. For negative controls, the step of incubation with primary antibodies was omitted.Table 1Primary antibodies utilized for immunochemistry and Western blot analysisAntibodies (Name)SuppliersCodeOriginImmunogensAntigen specificityConcentration used for immunohistochemistryConcentration used for Western blottingAQP1 (H-55)Santa Cruz Biotechnologysc-20810RabbitA peptide covering amino acid residues 215-269 of human AQP1AQP1800 ng/ml200 ng/mlAQP1 (1/22)Santa Cruz Biotechnologysc-32727MouseA peptide covering amino acid residues 249-269 of rat AQP1AQP14 mug/mlNAAQP4 (H-80)Santa Cruz Biotechnologysc-20812RabbitA peptide covering amino acid residues 244-323 mapping at the C-terminus of human AQP4AQP4800 ng/mlNAAbeta11-28 (12B2)Immunobiological Laboratory10027MouseHuman amyloid beta 11-28 peptideAbeta1-40, Abeta1-42, Abeta1-431 mug/mlNAGFAP (GA5)Nichirei422261MousePurified swine spinal cord GFAPGFAPPredilutedNACD68 (KP1)DakoN1577MouseLysosomal granules of human lung macrophagesCD68PredilutedNAFactor VIII (F8/86)Nichirei412191MouseHuman factor VIII-related antigenFactor VIII-related antigenPredilutedNANSENichirei422081RabbitPurified bovine brain NSENSEPredilutedNAACTB (AC-15)SigmaA1978MouseA synthetic peptide mimicking the N-terminus of beta-actinbeta-ActinNA500 ng/mlXpressInvitrogenR910-25MouseXpress epitope sequenceXpress6 mug/ml240 ng/mlAQP1 aquaporin-1, AQP4 aquaporin-4, Abeta amyloid-beta, GFAP glial fibrillary acidic protein, NSE neuron-specific enolase, ACTB beta-actin, NA not applied
###end p 16
###begin p 17
Primary antibodies utilized for immunochemistry and Western blot analysis
###end p 17
###begin p 18
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AQP1</italic>
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AQP4</italic>
###xml 36 41 36 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#946;</italic>
###xml 56 60 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFAP</italic>
###xml 94 97 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NSE</italic>
###xml 123 127 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 140 142 137 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NA</italic>
AQP1 aquaporin-1, AQP4 aquaporin-4, Abeta amyloid-beta, GFAP glial fibrillary acidic protein, NSE neuron-specific enolase, ACTB beta-actin, NA not applied
###end p 18
###begin p 19
###xml 69 70 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 74 75 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 90 91 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 95 96 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 113 114 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 118 119 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 315 316 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 320 321 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 336 337 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 341 342 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 359 360 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 364 365 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 583 584 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 595 596 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
In the motor cortex and hippocampus of each case, the number of Abeta+AQP1+ plaques, Abeta-AQP1+ spots, and Abeta+AQP1- plaques with size exceeding the diameter of 50 mum was counted in ten random fields at 400x microscopic magnification on the Olympus BX51 universal microscope. The average of percentages of Abeta+AQP1+ plaques, Abeta-AQP1+ spots, and Abeta+AQP1- plaques, the average of numbers of Abeta-immunoreactive plaques, and the average of numbers of AQP1-immunoreactive plaques/spots were compared between AD and non-AD cases by statistical analysis with a Mann-Whitney's U test. The P value of <0.05 was considered as significant.
###end p 19
###begin title 20
Immunocytochemistry
###end title 20
###begin p 21
###xml 473 478 <span type="species:ncbi:10090">mouse</span>
###xml 532 538 <span type="species:ncbi:9986">rabbit</span>
For immunocytochemistry, the cells on cover glasses were fixed with 4% PFA in 0.1 M phosphate buffer, pH 7.4 at RT for 5 min, followed by incubation with PBS containing 0.5% Triton X-100 at RT for 3 min. After blocking non-specific staining by PBS containing 10% NGS, the cells were incubated at RT for 30 min with a mixture of anti-GFAP antibody GA5 and anti-AQP1 antibody H-55. Then, they were incubated at RT for 30 min with a mixture of Alexa Fluor 568-conjugated anti-mouse IgG (Invitrogen) and Alexa Fluor 488-conjugated anti-rabbit IgG (Invitrogen). After several washes, they were mounted with an anti-fade reagent containing 4', 6'-diamidino-2-phenylindole (DAPI) (Invitrogen), and examined on the Olympus BX51 universal microscope. Negative controls were processed following all the steps, except for exposure to anti-AQP1 antibody.
###end p 21
###begin title 22
Western blot analysis
###end title 22
###begin p 23
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 734 740 <span type="species:ncbi:9986">rabbit</span>
###xml 1116 1121 <span type="species:ncbi:10090">mouse</span>
To prepare total protein extract, the cells were homogenized in RIPA lysis buffer, composed of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, and a cocktail of protease inhibitors (Sigma), followed by centrifugation at 12,000 rpm for 10 min at RT. The supernatant was collected, solved in the lysis buffer containing 2.5 M urea, and separated on a 12% SDS-PAGE gel [47]. The protein concentration was determined by a Bradford assay kit (BioRad, Hercules, CA, USA). After gel electrophoresis, the protein was transferred onto nitrocellulose membranes, and immunolabeled at RT overnight with anti-AQP1 antibody H-55. Then, the membranes were incubated at RT for 30 min with HRP-conjugated anti-rabbit IgG (Santa Cruz Biotechnology). The specific reaction was visualized by exposing to a chemiluminescent substrate (Pierce, Rockford, IL, USA). After the antibodies were stripped by incubating the membranes at 50degreesC for 30 min in stripping buffer, composed of 62.5 mM Tris-HCl, pH 6.7, 2% SDS and 100 mM 2-mercaptoethanol, the membranes were processed for relabeling with mouse monoclonal anti-beta-actin antibody AC-15 (Sigma).
###end p 23
###begin title 24
Immunoprecipitation analysis
###end title 24
###begin p 25
###xml 291 293 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 295 297 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 843 846 831 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 850 853 838 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 856 859 844 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 864 867 852 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 1338 1343 <span type="species:ncbi:10090">mouse</span>
###xml 1390 1396 <span type="species:ncbi:9986">rabbit</span>
###xml 1483 1488 <span type="species:ncbi:10090">mouse</span>
###xml 1492 1498 <span type="species:ncbi:9986">rabbit</span>
###xml 1632 1638 <span type="species:ncbi:9986">rabbit</span>
###xml 1680 1685 <span type="species:ncbi:10090">mouse</span>
To determine the molecular interaction between Abeta and AQP1, the N-terminal half of AQP1, including the transmembrane helices H1, H2 and H3 (amino acid residues 2-132; NTF), the C-terminal half of AQP1, including the transmembrane helices H4, H5 and H6 (amino acid residues 133-269; CTF) [10, 32] (GenBank accession No. NM_198098), and the C-terminal fragment beta (amino acid residues 597-695; CTFbeta) of amyloid precursor protein (APP) (NM_201414) were amplified by PCR using PfuTurbo DNA polymerase (Stratagene, La Jolla, CA, USA) and the sense and antisense primer sets following: 5'ccgaattccggccagcgagttcaagaagaag3' and 5'for the NTF of AQP1, 5'cggaattccggtgaactcgggccagggcct3' and 5'cggggtaccccgctatttgggcttcatctccac3' for the CTF of AQP1, and 5'and 5'cgggatcccgctagttctgcatctgctcaaagaa3' for the CTFbeta of APP. After digestion with EcoRI, KpnI, XbaI or BamHI (New England BioLabs, Beverly, MA, USA), the PCR products were cloned in the expression vectors pCMV-Myc (Clontech, Mountain View, CA, USA) or p3XFLAG-CMV7.1 (Sigma) to express a fusion protein with an N-terminal Flag or Myc tag. At 48 h after co-transfection of the vectors, HEK293 cells were homogenized in M-PER lysis buffer (Pierce) supplemented with a cocktail of protease inhibitors. After preclearance, the supernatant was incubated at 4degreesC overnight with mouse monoclonal anti-Flag M2 affinity gel (Sigma), rabbit polyclonal anti-Myc antibody-conjugated agarose (Sigma), or the same amount of normal mouse or rabbit IgG-conjugated agarose (Santa Cruz Biotechnology). After several washes, the immunoprecipitates were processed for Western blot with rabbit polyclonal anti-Myc antibody (Sigma) and mouse monoclonal anti-FLAG M2 antibody (Sigma).
###end p 25
###begin title 26
Cell imaging analysis
###end title 26
###begin p 27
###xml 108 112 102 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 416 420 404 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 443 446 431 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 450 453 438 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 456 459 444 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 464 467 452 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
The open reading frame (ORF) of the genes encoding AQP1 (amino acid residues 2-269) and the CTFbeta or Abeta1-42 of APP were amplified by PCR using PfuTurbo DNA polymerase and the sense and antisense primer sets following: 5'gccagcgagttcaagaagaagctc3' and 5'ctatttgggcttcatctccaccct3'for AQP1, 5'and 5'cgggatcccgctagttctgcatctgctcaaagaa3' for the CTFbeta of APP, and 5' cgggatcccgctacgctatgacaacaccgcccac3' for Abeta1-42. After digestion with EcoRI, KpnI, XhoI or BamHI, the PCR products were cloned in the expression vectors pDsRed-Express-C1 (Clontech) or pcDNA3.1/NT/GFP-TOPO (Invitrogen) to express a fusion protein with an N-terminal DsRed or GFP tag. At 24-48 h after co-transfection of the vectors, HEK293 cells were fixed briefly in 4% PFA and mounted with the anti-fade reagent containing DAPI.
###end p 27
###begin title 28
Tissue protein overlay analysis
###end title 28
###begin p 29
###xml 325 332 325 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 325 332 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
To identify AQP1-binding targets in brain tissues in situ, we prepared recombinant human AQP1 protein tagged with Xpress (AQP1-Xpress), serving as a probe for tissue protein overlay. The ORF of AQP1 gene amplified by PCR described above was cloned into a prokaryotic expression vector pTrcHis-TOPO (Invitrogen), expressed in E. coli, and purified to obtain a fusion protein having an N-terminal Xpress tag. After deparaffination, tissue sections were heated in 10 mM citrate sodium buffer, pH 6.0 by autoclave at 125degreesC for 30 s. They were treated with formic acid and 3% hydrogen peroxide, and then incubated at 4degreesC overnight with AQP1-Xpress at the concentration of 167 mug/ml or with the same amount of recombinant beta-galactosidase fragment tagged with Xpress (LacZ-Xpress), serving as a negative control. After washing with PBS, the tissue sections were incubated at RT for 45 min with anti-Xpress antibody, followed by incubation with HRP-conjugated secondary antibody, and colorized with DAB substrate. After inactivation of the antibodies by autoclaving, the tissue sections were processed for immunolabeling with anti-Abeta antibody, followed by incubation with AP-conjugated secondary antibody, and colorized with New Fuchsin substrate.
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
The close association of AQP1-expressing astrocytes with Abeta deposition in the cerebral cortex of AD
###end title 31
###begin p 32
###xml 504 505 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 516 517 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 537 538 534 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 555 556 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 680 681 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 687 688 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 717 718 714 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 884 885 881 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1084 1085 1078 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1088 1094 1082 1088 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1325 1326 1319 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1328 1331 1322 1325 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a&#8211;c</bold>
###xml 1338 1343 1332 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 1356 1359 1347 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1362 1363 1353 1354 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1370 1373 1361 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1385 1390 1376 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 1393 1394 1384 1385 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1401 1406 1392 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 1418 1421 1409 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1428 1429 1419 1420 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1436 1441 1427 1432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 1476 1479 1467 1470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1609 1610 1597 1598 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1094 1611 1088 1599 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Multipolar fibrillary astrocytes express AQP1 in the cerebral cortex of AD. The tissue sections of the motor cortex of AD patients were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. <bold>a&#8211;c</bold> AQP1 (<italic>brown</italic>) and A&#946; (<italic>red</italic>), <bold>d</bold> AQP1 (<italic>red</italic>) and GFAP (<italic>brown</italic>), <bold>e</bold> AQP1 (<italic>brown</italic>) and CD68 (<italic>red</italic>), and <bold>f</bold> AQP1 (<italic>brown</italic>) and factor VIII-related antigen (<italic>red</italic>). Multipolar fibrillary astrocytes expressing an intense AQP1 immunoreactivity are often located on the top of A&#946; deposition (<bold>a</bold>)</p>
###xml 1094 1611 1088 1599 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Multipolar fibrillary astrocytes express AQP1 in the cerebral cortex of AD. The tissue sections of the motor cortex of AD patients were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. <bold>a&#8211;c</bold> AQP1 (<italic>brown</italic>) and A&#946; (<italic>red</italic>), <bold>d</bold> AQP1 (<italic>red</italic>) and GFAP (<italic>brown</italic>), <bold>e</bold> AQP1 (<italic>brown</italic>) and CD68 (<italic>red</italic>), and <bold>f</bold> AQP1 (<italic>brown</italic>) and factor VIII-related antigen (<italic>red</italic>). Multipolar fibrillary astrocytes expressing an intense AQP1 immunoreactivity are often located on the top of A&#946; deposition (<bold>a</bold>)</p></caption>
###xml 1611 1611 1599 1599 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_387_Fig1_HTML" id="MO1"/>
###xml 1088 1611 1082 1599 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="33">Multipolar fibrillary astrocytes express AQP1 in the cerebral cortex of AD. The tissue sections of the motor cortex of AD patients were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. <bold>a&#8211;c</bold> AQP1 (<italic>brown</italic>) and A&#946; (<italic>red</italic>), <bold>d</bold> AQP1 (<italic>red</italic>) and GFAP (<italic>brown</italic>), <bold>e</bold> AQP1 (<italic>brown</italic>) and CD68 (<italic>red</italic>), and <bold>f</bold> AQP1 (<italic>brown</italic>) and factor VIII-related antigen (<italic>red</italic>). Multipolar fibrillary astrocytes expressing an intense AQP1 immunoreactivity are often located on the top of A&#946; deposition (<bold>a</bold>)</p></caption><graphic position="anchor" xlink:href="401_2008_387_Fig1_HTML" id="MO1"/></fig>
###xml 1611 1617 1599 1605 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1983 1984 1971 1972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1986 1987 1974 1975 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2035 2038 2023 2026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 2049 2054 2037 2042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 2057 2058 2045 2046 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2105 2110 2093 2098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 2123 2126 2108 2111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 2129 2130 2114 2115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2178 2181 2163 2166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 2193 2198 2178 2183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 2205 2208 2190 2193 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d&#8211;f</bold>
###xml 2256 2261 2241 2246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 2274 2277 2256 2259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 2326 2327 2308 2309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2331 2332 2313 2314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2334 2345 2316 2327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">thick arrow</italic>
###xml 2352 2353 2334 2335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2357 2358 2339 2340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2360 2369 2342 2351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowhead</italic>
###xml 2380 2381 2362 2363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2385 2386 2367 2368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2388 2399 2370 2381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">thin arrows</italic>
###xml 2418 2419 2400 2401 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1617 2420 1605 2402 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">Multipolar fibrillary astrocytes express AQP1 and AQP4 in the cerebral cortex of AD and other neurological diseases. The tissue sections of the motor cortex and the hippocampus of the patients with AD, Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. <bold>a</bold> the motor cortex of the patient with AD; AQP1 (<italic>red</italic>) and NSE (<italic>brown</italic>), <bold>b</bold> the hippocampus of the patient with AD; AQP4 (<italic>brown</italic>) and A&#946; (<italic>red</italic>), <bold>c</bold> the hippocampus of the patient with ALS; AQP1 (<italic>red</italic>) and AQP4 (<italic>brown</italic>), and <bold>d&#8211;f</bold> the motor cortex of the patient with PD; AQP1 (<italic>brown</italic>) and A&#946; (<italic>red</italic>). Three distinct populations of astrocytes, AQP1<sup>+</sup>AQP4<sup>+</sup> (<italic>thick arrow</italic>), AQP1<sup>+</sup>AQP4<sup>&#8722;</sup> (<italic>arrowhead</italic>), and AQP1<sup>&#8722;</sup>AQP4<sup>+</sup> (<italic>thin arrows</italic>), are identified (<bold>c</bold>)</p>
###xml 1617 2420 1605 2402 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">Multipolar fibrillary astrocytes express AQP1 and AQP4 in the cerebral cortex of AD and other neurological diseases. The tissue sections of the motor cortex and the hippocampus of the patients with AD, Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. <bold>a</bold> the motor cortex of the patient with AD; AQP1 (<italic>red</italic>) and NSE (<italic>brown</italic>), <bold>b</bold> the hippocampus of the patient with AD; AQP4 (<italic>brown</italic>) and A&#946; (<italic>red</italic>), <bold>c</bold> the hippocampus of the patient with ALS; AQP1 (<italic>red</italic>) and AQP4 (<italic>brown</italic>), and <bold>d&#8211;f</bold> the motor cortex of the patient with PD; AQP1 (<italic>brown</italic>) and A&#946; (<italic>red</italic>). Three distinct populations of astrocytes, AQP1<sup>+</sup>AQP4<sup>+</sup> (<italic>thick arrow</italic>), AQP1<sup>+</sup>AQP4<sup>&#8722;</sup> (<italic>arrowhead</italic>), and AQP1<sup>&#8722;</sup>AQP4<sup>+</sup> (<italic>thin arrows</italic>), are identified (<bold>c</bold>)</p></caption>
###xml 2420 2420 2402 2402 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_387_Fig2_HTML" id="MO2"/>
###xml 1611 2420 1599 2402 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="34">Multipolar fibrillary astrocytes express AQP1 and AQP4 in the cerebral cortex of AD and other neurological diseases. The tissue sections of the motor cortex and the hippocampus of the patients with AD, Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. <bold>a</bold> the motor cortex of the patient with AD; AQP1 (<italic>red</italic>) and NSE (<italic>brown</italic>), <bold>b</bold> the hippocampus of the patient with AD; AQP4 (<italic>brown</italic>) and A&#946; (<italic>red</italic>), <bold>c</bold> the hippocampus of the patient with ALS; AQP1 (<italic>red</italic>) and AQP4 (<italic>brown</italic>), and <bold>d&#8211;f</bold> the motor cortex of the patient with PD; AQP1 (<italic>brown</italic>) and A&#946; (<italic>red</italic>). Three distinct populations of astrocytes, AQP1<sup>+</sup>AQP4<sup>+</sup> (<italic>thick arrow</italic>), AQP1<sup>+</sup>AQP4<sup>&#8722;</sup> (<italic>arrowhead</italic>), and AQP1<sup>&#8722;</sup>AQP4<sup>+</sup> (<italic>thin arrows</italic>), are identified (<bold>c</bold>)</p></caption><graphic position="anchor" xlink:href="401_2008_387_Fig2_HTML" id="MO2"/></fig>
###xml 1216 1224 <span type="species:ncbi:9606">patients</span>
###xml 1801 1809 <span type="species:ncbi:9606">patients</span>
###xml 2012 2019 <span type="species:ncbi:9606">patient</span>
###xml 2082 2089 <span type="species:ncbi:9606">patient</span>
###xml 2154 2161 <span type="species:ncbi:9606">patient</span>
###xml 2233 2240 <span type="species:ncbi:9606">patient</span>
First, we studied AQP1 and AQP4 expression in the motor cortex and hippocampus of 11 AD cases and 16 age-matched other neurological disease (non-AD) cases by double-labeling immunohistochemistry with a combination of anti-AQP1 antibody, anti-AQP4 antibody, anti-Abeta antibody, and antibodies against cell type-specific markers. In all cases, examined, AQP1 was expressed exclusively in multipolar fibrillary astrocytes with highly-branched processes that often surround blood vessels and neurons (Figs. 1a, b, d-f, 2a, c-e). Neither NSE+ neurons nor CD68+ microglia nor factor VIII-related antigen-positive vascular endothelial cells were immunolabeled with AQP1 antibody (Figs. 1e, f, 2a). Approximately 70% of AQP1+ multipolar fibrillary cells coexpressed an intense GFAP immunoreactivity, verifying that they represent a subpopulation of astrocytes with a unique morphology (Fig. 1d). Importantly, AQP1-expressing astrocytes were either often located on the top of or in close proximity to Abeta plaques in the motor cortex and hippocampus of AD, but rarely in non-AD cases (Fig. 1a).Fig. 1Multipolar fibrillary astrocytes express AQP1 in the cerebral cortex of AD. The tissue sections of the motor cortex of AD patients were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table 1. a-c AQP1 (brown) and Abeta (red), d AQP1 (red) and GFAP (brown), e AQP1 (brown) and CD68 (red), and f AQP1 (brown) and factor VIII-related antigen (red). Multipolar fibrillary astrocytes expressing an intense AQP1 immunoreactivity are often located on the top of Abeta deposition (a)Fig. 2Multipolar fibrillary astrocytes express AQP1 and AQP4 in the cerebral cortex of AD and other neurological diseases. The tissue sections of the motor cortex and the hippocampus of the patients with AD, Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table 1. a the motor cortex of the patient with AD; AQP1 (red) and NSE (brown), b the hippocampus of the patient with AD; AQP4 (brown) and Abeta (red), c the hippocampus of the patient with ALS; AQP1 (red) and AQP4 (brown), and d-f the motor cortex of the patient with PD; AQP1 (brown) and Abeta (red). Three distinct populations of astrocytes, AQP1+AQP4+ (thick arrow), AQP1+AQP4- (arrowhead), and AQP1-AQP4+ (thin arrows), are identified (c)
###end p 32
###begin p 33
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 234 237 234 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a&#8211;c</bold>
###xml 244 249 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 262 265 259 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 268 269 265 266 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 276 279 273 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 291 296 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 299 300 296 297 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 307 312 304 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 324 327 321 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 334 335 331 332 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 342 347 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 382 385 379 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 515 516 509 510 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
Multipolar fibrillary astrocytes express AQP1 in the cerebral cortex of AD. The tissue sections of the motor cortex of AD patients were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table 1. a-c AQP1 (brown) and Abeta (red), d AQP1 (red) and GFAP (brown), e AQP1 (brown) and CD68 (red), and f AQP1 (brown) and factor VIII-related antigen (red). Multipolar fibrillary astrocytes expressing an intense AQP1 immunoreactivity are often located on the top of Abeta deposition (a)
###end p 33
###begin p 34
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 369 370 369 370 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 418 421 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 440 441 440 441 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 488 493 488 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 506 509 503 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 512 513 509 510 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 561 564 558 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 576 581 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 588 591 585 588 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d&#8211;f</bold>
###xml 639 644 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 657 660 651 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 709 710 703 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 714 715 708 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 717 728 711 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">thick arrow</italic>
###xml 735 736 729 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 740 741 734 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 743 752 737 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrowhead</italic>
###xml 763 764 757 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 768 769 762 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 771 782 765 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">thin arrows</italic>
###xml 801 802 795 796 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
###xml 395 402 <span type="species:ncbi:9606">patient</span>
###xml 465 472 <span type="species:ncbi:9606">patient</span>
###xml 537 544 <span type="species:ncbi:9606">patient</span>
###xml 616 623 <span type="species:ncbi:9606">patient</span>
Multipolar fibrillary astrocytes express AQP1 and AQP4 in the cerebral cortex of AD and other neurological diseases. The tissue sections of the motor cortex and the hippocampus of the patients with AD, Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table 1. a the motor cortex of the patient with AD; AQP1 (red) and NSE (brown), b the hippocampus of the patient with AD; AQP4 (brown) and Abeta (red), c the hippocampus of the patient with ALS; AQP1 (red) and AQP4 (brown), and d-f the motor cortex of the patient with PD; AQP1 (brown) and Abeta (red). Three distinct populations of astrocytes, AQP1+AQP4+ (thick arrow), AQP1+AQP4- (arrowhead), and AQP1-AQP4+ (thin arrows), are identified (c)
###end p 34
###begin p 35
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 526 527 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 531 532 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 538 539 538 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 543 544 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 554 555 554 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 559 560 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 693 694 693 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 698 699 698 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
In contrast, AQP4 immunoreactivity was distributed more diffusely in the whole neuropil, gliotic and perivascular lesions, and the pia matter in the cerebral cortex of both AD and non-AD cases, although the staining was more intense in AD brains (Fig. 2b; Supplementary Fig. 2). In all the cases, multipolar fibrillary astrocytes expressing an intense immunoreactivity for AQP4 were less prominently found,when compared with AQP1-expressing astrocytes. Double labeling identified three distinct populations of astrocytes, AQP1+AQP4+, AQP1+AQP4-, and AQP1-AQP4+, suggesting that AQP1 and AQP4 might play an overlapping but non-redundant role in astrocytic water channel function (Fig. 2c). AQP1+AQP4+ cells consisted of approximately 15% of all AQP-immunoreactive cells. Owing to the diffuse distribution of intense neuropil staining of AQP4, we could not clearly discriminate AQP4-immunoreactive astrocytes with or without a contact with Abeta, making it highly difficult to count exactly the number of AQP4-expressing astrocytes located in the proximity to Abeta plaques.
###end p 35
###begin p 36
###xml 242 243 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 247 248 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 264 265 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 268 269 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 278 279 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 283 284 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 298 299 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 302 303 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 316 317 304 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 321 322 309 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 338 339 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 342 343 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 483 484 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 526 527 510 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 531 532 515 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 635 636 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 670 671 654 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 753 754 734 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 758 759 739 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 860 861 841 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 895 896 876 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1620 1621 1566 1567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1665 1666 1608 1609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1709 1710 1649 1650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1757 1758 1697 1698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1992 1993 1926 1927 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1997 1998 1931 1932 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2290 2296 2218 2224 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 2625 2626 2544 2545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2630 2631 2549 2550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2646 2647 2562 2563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2651 2652 2567 2568 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2671 2672 2584 2585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2676 2677 2589 2590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2880 2881 2789 2790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2885 2886 2794 2795 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2894 2895 2800 2801 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2899 2900 2805 2806 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2909 2910 2812 2813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2914 2915 2817 2818 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2979 2982 2882 2885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 3008 3009 2911 2912 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 3024 3025 2927 2928 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 3040 3042 2943 2945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 3057 3058 2960 2961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3076 3077 2979 2980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 3099 3100 3002 3003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2296 3112 2224 3015 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">The number of AQP1 and A&#946;-immunoreactive plaques in the cerebral cortex of AD. The tissue sections of the motor cortex and the hippocampus of 11 AD patients and 16 age-matched non-AD patients were processed for double-labeling immunohistochemistry with anti-AQP1 antibody H-55 and anti-A&#946; antibody 12B2. The number of A&#946;<sup>+</sup>AQP1<sup>+</sup> plaques, A&#946;<sup>+</sup>AQP1<sup>&#8722;</sup> plaques, and A&#946;<sup>&#8722;</sup>AQP1<sup>+</sup> spots with the size exceeding the diameter of 50&#160;&#956;m was counted by random scanning of the cerebral cortex at a 400&#215; magnification under microscope. The percentage of immunoreactive plaques/spots, A&#946;<sup>+</sup>AQP1<sup>+</sup>, A&#946; <sup>+</sup>AQP1<sup>&#8722;</sup> or A&#946;<sup>&#8722;</sup>AQP1<sup>+</sup>, per the total was calculated, and the average is shown as the <italic>bar</italic> with standard deviation. <bold>a</bold> Motor cortex. <bold>b</bold> Hippocampus. *<italic>P&#160;</italic>=&#160;1.092E-05, **<italic>P</italic>&#160;=&#160;1.865E-05, ***&#160;<italic>P</italic>&#160;=&#160;1.410E-05, and ****<italic>P</italic>&#160;=&#160;5.035E-04</p>
###xml 2296 3112 2224 3015 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">The number of AQP1 and A&#946;-immunoreactive plaques in the cerebral cortex of AD. The tissue sections of the motor cortex and the hippocampus of 11 AD patients and 16 age-matched non-AD patients were processed for double-labeling immunohistochemistry with anti-AQP1 antibody H-55 and anti-A&#946; antibody 12B2. The number of A&#946;<sup>+</sup>AQP1<sup>+</sup> plaques, A&#946;<sup>+</sup>AQP1<sup>&#8722;</sup> plaques, and A&#946;<sup>&#8722;</sup>AQP1<sup>+</sup> spots with the size exceeding the diameter of 50&#160;&#956;m was counted by random scanning of the cerebral cortex at a 400&#215; magnification under microscope. The percentage of immunoreactive plaques/spots, A&#946;<sup>+</sup>AQP1<sup>+</sup>, A&#946; <sup>+</sup>AQP1<sup>&#8722;</sup> or A&#946;<sup>&#8722;</sup>AQP1<sup>+</sup>, per the total was calculated, and the average is shown as the <italic>bar</italic> with standard deviation. <bold>a</bold> Motor cortex. <bold>b</bold> Hippocampus. *<italic>P&#160;</italic>=&#160;1.092E-05, **<italic>P</italic>&#160;=&#160;1.865E-05, ***&#160;<italic>P</italic>&#160;=&#160;1.410E-05, and ****<italic>P</italic>&#160;=&#160;5.035E-04</p></caption>
###xml 3112 3112 3015 3015 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_387_Fig3_HTML" id="MO3"/>
###xml 2290 3112 2218 3015 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="37">The number of AQP1 and A&#946;-immunoreactive plaques in the cerebral cortex of AD. The tissue sections of the motor cortex and the hippocampus of 11 AD patients and 16 age-matched non-AD patients were processed for double-labeling immunohistochemistry with anti-AQP1 antibody H-55 and anti-A&#946; antibody 12B2. The number of A&#946;<sup>+</sup>AQP1<sup>+</sup> plaques, A&#946;<sup>+</sup>AQP1<sup>&#8722;</sup> plaques, and A&#946;<sup>&#8722;</sup>AQP1<sup>+</sup> spots with the size exceeding the diameter of 50&#160;&#956;m was counted by random scanning of the cerebral cortex at a 400&#215; magnification under microscope. The percentage of immunoreactive plaques/spots, A&#946;<sup>+</sup>AQP1<sup>+</sup>, A&#946; <sup>+</sup>AQP1<sup>&#8722;</sup> or A&#946;<sup>&#8722;</sup>AQP1<sup>+</sup>, per the total was calculated, and the average is shown as the <italic>bar</italic> with standard deviation. <bold>a</bold> Motor cortex. <bold>b</bold> Hippocampus. *<italic>P&#160;</italic>=&#160;1.092E-05, **<italic>P</italic>&#160;=&#160;1.865E-05, ***&#160;<italic>P</italic>&#160;=&#160;1.410E-05, and ****<italic>P</italic>&#160;=&#160;5.035E-04</p></caption><graphic position="anchor" xlink:href="401_2008_387_Fig3_HTML" id="MO3"/></fig>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 2447 2455 <span type="species:ncbi:9606">patients</span>
###xml 2482 2490 <span type="species:ncbi:9606">patients</span>
Next, tissue sections of the motor cortex and hippocampus of AD and non-AD patients were processed for double-labeling immunohistochemistry with a combination of anti-AQP1 antibody and anti-Abeta antibody. Then, we counted the number of Abeta+AQP1+ plaques (Figs. 1a, 2d), Abeta-AQP1+ spots (Figs. 1b, 2e), and Abeta+AQP1- plaques (Figs. 1c, 2f) with the size exceeding the diameter of 50 mum, by random scanning of the cerebral cortex at a 400x magnification under microscope (Fig. 3a, b). The average of percentages of Abeta+AQP1+ plaques was significantly greater in both the motor cortex and hippocampus of AD than that of non-AD (P = 1.092E-05 in the motor cortex; P = 1.410E-05 in the hippocampus). In contrast, the average of percentages of Abeta-AQP1+ spots was significantly greater in both the motor cortex and hippocampus of non-AD than that of AD (P = 1.865E-05 in the motor cortex; P = 5.035E-04 in the hippocampus). By counting of ten random high magnification fields, the average of total number of Abeta-immunoreactive plaques or AQP1-immunoreactive plaques/spots larger than 50 muM diameter was 16.2 +/- 4.7 for Abeta and 16.3 +/- 4.4 for AQP1 in the motor cortex of AD, and 15.1 +/- 4.1 for Abeta and 16.5 +/- 4.0 for AQP1 in the hippocampus of AD. In contrast, it was 0.6 +/- 1.9 for Abeta and 2.7 +/- 1.8 for AQP1 in the motor cortex of non-AD, and 2.6 +/- 4.5 for Abeta and 8.6 +/- 6.1 for AQP1 in the hippocampus of non-AD. Thus, the average number of Abeta-immunoreactive plaques and AQP1-immunoreactive plaques/spots, was elevated significantly in the cerebral cortex of AD compared with non-AD (P = 1.217E-05 for Abeta in the motor cortex; P = 6.416E-05 for Abeta in the hippocampus; P = 1.092E-05 for AQP1 in the motor cortex; and P = 0.003 for AQP1 in the hippocampus). All of these observations suggest a close association of AQP1 with Abeta deposition in the cerebral cortex of AD. Alternatively, the possibility should be considered that the population of Abeta +AQP1+ plaques is much smaller in non-AD brains, because there existed less amounts of Abeta deposition and smaller numbers of AQP1-immunoreactive astrocytes in the brains of non-AD cases. In this setting, Abeta deposition might not be obligatory for induction of the astrocytic expression of AQP1.Fig. 3The number of AQP1 and Abeta-immunoreactive plaques in the cerebral cortex of AD. The tissue sections of the motor cortex and the hippocampus of 11 AD patients and 16 age-matched non-AD patients were processed for double-labeling immunohistochemistry with anti-AQP1 antibody H-55 and anti-Abeta antibody 12B2. The number of Abeta+AQP1+ plaques, Abeta+AQP1- plaques, and Abeta-AQP1+ spots with the size exceeding the diameter of 50 mum was counted by random scanning of the cerebral cortex at a 400x magnification under microscope. The percentage of immunoreactive plaques/spots, Abeta+AQP1+, Abeta +AQP1- or Abeta-AQP1+, per the total was calculated, and the average is shown as the bar with standard deviation. a Motor cortex. b Hippocampus. *P = 1.092E-05, **P = 1.865E-05, *** P = 1.410E-05, and ****P = 5.035E-04
###end p 36
###begin p 37
###xml 329 330 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 334 335 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 350 351 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 355 356 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 375 376 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 380 381 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 584 585 565 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 589 590 570 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 598 599 576 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 603 604 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 613 614 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 618 619 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 683 686 658 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 712 713 687 688 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 728 729 703 704 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 744 746 719 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 761 762 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 780 781 755 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 803 804 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
The number of AQP1 and Abeta-immunoreactive plaques in the cerebral cortex of AD. The tissue sections of the motor cortex and the hippocampus of 11 AD patients and 16 age-matched non-AD patients were processed for double-labeling immunohistochemistry with anti-AQP1 antibody H-55 and anti-Abeta antibody 12B2. The number of Abeta+AQP1+ plaques, Abeta+AQP1- plaques, and Abeta-AQP1+ spots with the size exceeding the diameter of 50 mum was counted by random scanning of the cerebral cortex at a 400x magnification under microscope. The percentage of immunoreactive plaques/spots, Abeta+AQP1+, Abeta +AQP1- or Abeta-AQP1+, per the total was calculated, and the average is shown as the bar with standard deviation. a Motor cortex. b Hippocampus. *P = 1.092E-05, **P = 1.865E-05, *** P = 1.410E-05, and ****P = 5.035E-04
###end p 37
###begin title 38
###xml 49 54 <span type="species:ncbi:9606">human</span>
The expression and induction of AQP1 in cultured human astrocytes
###end title 38
###begin p 39
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 1036 1040 1033 1037 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 1049 1053 1043 1047 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-40</sub>
###xml 1235 1236 1228 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 1602 1603 1595 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 1823 1829 1816 1822 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 2031 2032 2024 2025 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2060 2061 2053 2054 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2090 2091 2083 2084 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2102 2103 2095 2096 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2113 2114 2106 2107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2119 2120 2112 2113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1829 2130 1822 2123 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Cultured human astrocytes express AQP1 immunoreactivity. Cultured human astrocytes were processed for triple-labeling immunocytochemistry with anti-AQP1 antibody H-55, anti-GFAP antibody GA5, and DAPI. <bold>a</bold> AQP1, lower magnification; <bold>b</bold> AQP1, higher magnification; <bold>c</bold> GFAP, and <bold>d</bold> merge of <bold>b</bold> and <bold>c</bold> with DAPI</p>
###xml 1829 2130 1822 2123 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Cultured human astrocytes express AQP1 immunoreactivity. Cultured human astrocytes were processed for triple-labeling immunocytochemistry with anti-AQP1 antibody H-55, anti-GFAP antibody GA5, and DAPI. <bold>a</bold> AQP1, lower magnification; <bold>b</bold> AQP1, higher magnification; <bold>c</bold> GFAP, and <bold>d</bold> merge of <bold>b</bold> and <bold>c</bold> with DAPI</p></caption>
###xml 2130 2130 2123 2123 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_387_Fig4_HTML" id="MO4"/>
###xml 1823 2130 1816 2123 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="40">Cultured human astrocytes express AQP1 immunoreactivity. Cultured human astrocytes were processed for triple-labeling immunocytochemistry with anti-AQP1 antibody H-55, anti-GFAP antibody GA5, and DAPI. <bold>a</bold> AQP1, lower magnification; <bold>b</bold> AQP1, higher magnification; <bold>c</bold> GFAP, and <bold>d</bold> merge of <bold>b</bold> and <bold>c</bold> with DAPI</p></caption><graphic position="anchor" xlink:href="401_2008_387_Fig4_HTML" id="MO4"/></fig>
###xml 2130 2136 2123 2129 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 2426 2432 2416 2422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panels</italic>
###xml 2504 2509 2494 2499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 2509 2510 2499 2500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 2511 2512 2501 2502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 2527 2532 2517 2522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 2532 2533 2522 2523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 2538 2539 2528 2529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5</italic>
###xml 2558 2563 2548 2553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 2563 2564 2553 2554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">6</italic>
###xml 2565 2567 2555 2557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">13</italic>
###xml 2574 2579 2564 2569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 2581 2582 2571 2572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 2583 2585 2573 2575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">13</italic>
###xml 2659 2663 2645 2649 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-40</sub>
###xml 2689 2693 2671 2675 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 2796 2805 2775 2784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">all trans</italic>
###xml 2136 3165 2129 3139 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">AQP1 protein levels in cultured human astrocytes exposed to various stimuli. Cultured human astrocytes were exposed for 48&#160;h to the stimuli, and then processed for Western blot analysis with anti-AQP1 antibody H-55. The identical blot was relabeled with anti-&#946;-actin antibody AC-15. The <italic>panels</italic> consist of three distinct sets of experiments, composed of the set #1 (<italic>lanes</italic><italic>1</italic>&#8211;<italic>3</italic>), the set #2 (<italic>lanes</italic><italic>4</italic> and <italic>5</italic>), and the set #3 (<italic>lanes</italic><italic>6</italic>&#8211;<italic>13</italic>). The <italic>lanes</italic> (<italic>1</italic>&#8211;<italic>13</italic>) represent (1, 4, 6) untreated or vehicle-treated cells, (2) 10&#160;&#956;M A&#946;<sub>1-40</sub> peptide, (3) 10&#160;&#956;M A&#946;<sub>1-42</sub> peptide, (5) 100&#160;mM NaCl, (7) 100&#160;&#956;M sodium nitroprusside, (8) 100&#160;&#956;M hydrogen peroxide, (9) 10&#160;&#956;M <italic>all trans</italic> retinoic acid, (10) 100&#160;nM phorbol 12-myristate 13-acetate, (11) 1&#160;mM dibutyryl cyclic AMP, (12) 10&#160;&#956;M MG-132, and (13) 1&#160;&#956;M thapsigargin. Twenty-five microgram of protein was loaded on each lane. The expression levels indicate the ratio of AQP1 protein level of treated cells versus untreated cells, which were standardized against &#946;-actin protein level</p>
###xml 2136 3165 2129 3139 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">AQP1 protein levels in cultured human astrocytes exposed to various stimuli. Cultured human astrocytes were exposed for 48&#160;h to the stimuli, and then processed for Western blot analysis with anti-AQP1 antibody H-55. The identical blot was relabeled with anti-&#946;-actin antibody AC-15. The <italic>panels</italic> consist of three distinct sets of experiments, composed of the set #1 (<italic>lanes</italic><italic>1</italic>&#8211;<italic>3</italic>), the set #2 (<italic>lanes</italic><italic>4</italic> and <italic>5</italic>), and the set #3 (<italic>lanes</italic><italic>6</italic>&#8211;<italic>13</italic>). The <italic>lanes</italic> (<italic>1</italic>&#8211;<italic>13</italic>) represent (1, 4, 6) untreated or vehicle-treated cells, (2) 10&#160;&#956;M A&#946;<sub>1-40</sub> peptide, (3) 10&#160;&#956;M A&#946;<sub>1-42</sub> peptide, (5) 100&#160;mM NaCl, (7) 100&#160;&#956;M sodium nitroprusside, (8) 100&#160;&#956;M hydrogen peroxide, (9) 10&#160;&#956;M <italic>all trans</italic> retinoic acid, (10) 100&#160;nM phorbol 12-myristate 13-acetate, (11) 1&#160;mM dibutyryl cyclic AMP, (12) 10&#160;&#956;M MG-132, and (13) 1&#160;&#956;M thapsigargin. Twenty-five microgram of protein was loaded on each lane. The expression levels indicate the ratio of AQP1 protein level of treated cells versus untreated cells, which were standardized against &#946;-actin protein level</p></caption>
###xml 3165 3165 3139 3139 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_387_Fig5_HTML" id="MO5"/>
###xml 2130 3165 2123 3139 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="41">AQP1 protein levels in cultured human astrocytes exposed to various stimuli. Cultured human astrocytes were exposed for 48&#160;h to the stimuli, and then processed for Western blot analysis with anti-AQP1 antibody H-55. The identical blot was relabeled with anti-&#946;-actin antibody AC-15. The <italic>panels</italic> consist of three distinct sets of experiments, composed of the set #1 (<italic>lanes</italic><italic>1</italic>&#8211;<italic>3</italic>), the set #2 (<italic>lanes</italic><italic>4</italic> and <italic>5</italic>), and the set #3 (<italic>lanes</italic><italic>6</italic>&#8211;<italic>13</italic>). The <italic>lanes</italic> (<italic>1</italic>&#8211;<italic>13</italic>) represent (1, 4, 6) untreated or vehicle-treated cells, (2) 10&#160;&#956;M A&#946;<sub>1-40</sub> peptide, (3) 10&#160;&#956;M A&#946;<sub>1-42</sub> peptide, (5) 100&#160;mM NaCl, (7) 100&#160;&#956;M sodium nitroprusside, (8) 100&#160;&#956;M hydrogen peroxide, (9) 10&#160;&#956;M <italic>all trans</italic> retinoic acid, (10) 100&#160;nM phorbol 12-myristate 13-acetate, (11) 1&#160;mM dibutyryl cyclic AMP, (12) 10&#160;&#956;M MG-132, and (13) 1&#160;&#956;M thapsigargin. Twenty-five microgram of protein was loaded on each lane. The expression levels indicate the ratio of AQP1 protein level of treated cells versus untreated cells, which were standardized against &#946;-actin protein level</p></caption><graphic position="anchor" xlink:href="401_2008_387_Fig5_HTML" id="MO5"/></fig>
###xml 141 146 <span type="species:ncbi:9606">human</span>
###xml 223 228 <span type="species:ncbi:9606">human</span>
###xml 534 539 <span type="species:ncbi:9606">human</span>
###xml 837 842 <span type="species:ncbi:9606">human</span>
###xml 1655 1660 <span type="species:ncbi:9606">human</span>
###xml 1838 1843 <span type="species:ncbi:9606">human</span>
###xml 1895 1900 <span type="species:ncbi:9606">human</span>
###xml 2168 2173 <span type="species:ncbi:9606">human</span>
###xml 2222 2227 <span type="species:ncbi:9606">human</span>
Since a subset of astrocytes intensely expressed AQP1 in AD and non-AD brains, in the next step, we investigated AQP1 expression in cultured human astrocytes. Consistent with high levels of AQP1 mRNA expression in cultured human astrocytes, as we reported previously [47], virtually all of them expressed constitutively a discernible immunoreactivity for AQP1, located mostly on the plasma membrane and less abundantly in the cytoplasm (Fig. 4a-d). The expression of AQP1 in astrocytes was further validated by Western blot. Cultured human astrocytes expressed constitutively a substantial amount of AQP1 protein with a molecular weight of 28-kDa, which represents the non-glycosylated form (Fig. 5a, lanes 1, 4, 6). They did not consistently express the glycosylated form with a larger molecular weight (data not shown). Then, cultured human astrocytes were exposed for 48 h to various stimuli that potentially affect the levels of AQP1 expression. The levels of AQP1 protein expression were not affected by treatment with either Abeta1-42 or Abeta1-40 peptide, but elevated markedly by exposure to 100 mM NaCl, modestly by 10 muM MG-132, and reduced substantially by treatment with 100 nM phorbol 12-myristate 13-acetate (PMA) (Fig. 5, panel a, lanes 2, 3, 5, 10, 12). Upregulation by NaCl and downregulation by PMA were verified by real-time RT-PCR analysis (Supplementary Fig. 3). In contrast, the treatment with either sodium nitroprusside (SNP), hydrogen peroxide, retinoic acid (RA), dibutyryl cyclic AMP (dbcAMP), or thapsigargin (TG) did not affect the levels of AQP1 protein expression (Fig. 5 lanes 7, 8, 9, 11, 13). These results suggest that human astrocytes that express substantial amounts of AQP1 protein under the baseline culture condition are fairly resistant to induction of AQP1 by non-osmotic stimuli.Fig. 4Cultured human astrocytes express AQP1 immunoreactivity. Cultured human astrocytes were processed for triple-labeling immunocytochemistry with anti-AQP1 antibody H-55, anti-GFAP antibody GA5, and DAPI. a AQP1, lower magnification; b AQP1, higher magnification; c GFAP, and d merge of b and c with DAPIFig. 5AQP1 protein levels in cultured human astrocytes exposed to various stimuli. Cultured human astrocytes were exposed for 48 h to the stimuli, and then processed for Western blot analysis with anti-AQP1 antibody H-55. The identical blot was relabeled with anti-beta-actin antibody AC-15. The panels consist of three distinct sets of experiments, composed of the set #1 (lanes1-3), the set #2 (lanes4 and 5), and the set #3 (lanes6-13). The lanes (1-13) represent (1, 4, 6) untreated or vehicle-treated cells, (2) 10 muM Abeta1-40 peptide, (3) 10 muM Abeta1-42 peptide, (5) 100 mM NaCl, (7) 100 muM sodium nitroprusside, (8) 100 muM hydrogen peroxide, (9) 10 muM all trans retinoic acid, (10) 100 nM phorbol 12-myristate 13-acetate, (11) 1 mM dibutyryl cyclic AMP, (12) 10 muM MG-132, and (13) 1 muM thapsigargin. Twenty-five microgram of protein was loaded on each lane. The expression levels indicate the ratio of AQP1 protein level of treated cells versus untreated cells, which were standardized against beta-actin protein level
###end p 39
###begin p 40
###xml 202 203 202 203 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 231 232 231 232 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 261 262 261 262 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 273 274 273 274 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 284 285 284 285 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 290 291 290 291 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Cultured human astrocytes express AQP1 immunoreactivity. Cultured human astrocytes were processed for triple-labeling immunocytochemistry with anti-AQP1 antibody H-55, anti-GFAP antibody GA5, and DAPI. a AQP1, lower magnification; b AQP1, higher magnification; c GFAP, and d merge of b and c with DAPI
###end p 40
###begin p 41
###xml 290 296 287 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panels</italic>
###xml 368 373 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 373 374 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 375 376 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 391 396 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 396 397 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 402 403 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5</italic>
###xml 422 427 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 427 428 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">6</italic>
###xml 429 431 426 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">13</italic>
###xml 438 443 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 445 446 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 447 449 444 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">13</italic>
###xml 523 527 516 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-40</sub>
###xml 553 557 542 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 660 669 646 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">all trans</italic>
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 86 91 <span type="species:ncbi:9606">human</span>
AQP1 protein levels in cultured human astrocytes exposed to various stimuli. Cultured human astrocytes were exposed for 48 h to the stimuli, and then processed for Western blot analysis with anti-AQP1 antibody H-55. The identical blot was relabeled with anti-beta-actin antibody AC-15. The panels consist of three distinct sets of experiments, composed of the set #1 (lanes1-3), the set #2 (lanes4 and 5), and the set #3 (lanes6-13). The lanes (1-13) represent (1, 4, 6) untreated or vehicle-treated cells, (2) 10 muM Abeta1-40 peptide, (3) 10 muM Abeta1-42 peptide, (5) 100 mM NaCl, (7) 100 muM sodium nitroprusside, (8) 100 muM hydrogen peroxide, (9) 10 muM all trans retinoic acid, (10) 100 nM phorbol 12-myristate 13-acetate, (11) 1 mM dibutyryl cyclic AMP, (12) 10 muM MG-132, and (13) 1 muM thapsigargin. Twenty-five microgram of protein was loaded on each lane. The expression levels indicate the ratio of AQP1 protein level of treated cells versus untreated cells, which were standardized against beta-actin protein level
###end p 41
###begin title 42
Molecular interaction of AQP1 and CTFbeta of APP
###end title 42
###begin p 43
###xml 307 311 301 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 920 921 905 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 959 965 944 950 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 1019 1020 1001 1002 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1022 1023 1004 1005 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1445 1446 1424 1425 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1496 1497 1472 1473 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1551 1556 1524 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 1558 1559 1531 1532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 1560 1561 1533 1534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 1684 1685 1657 1658 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1737 1740 1704 1707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">-42</sub>
###xml 1901 1902 1868 1869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1933 1934 1900 1901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1970 1971 1934 1935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1981 1982 1945 1946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1987 1988 1951 1952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 2000 2001 1964 1965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 2032 2033 1996 1997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 2039 2043 2000 2004 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 2075 2076 2036 2037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 2086 2087 2047 2048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 2092 2093 2053 2054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 965 2103 950 2064 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Molecular interaction of AQP1 and the CTF&#946; of APP. <bold>a</bold>, <bold>b</bold> Immunoprecipitation (IP) analysis. The C-terminal fragment-beta (CTF&#946;) of amyloid precursor protein (APP) was expressed as a Flag-tagged fusion protein, while either the NTF or the CTF of AQP1 was expressed as a Myc-tagged fusion protein. They were coexpressed in HEK293 cells, and processed for pull-down with anti-Flag or anti-Myc antibody, followed by Western blot reciprocally with anti-Myc or anti-Flag antibody. <bold>a</bold> The interaction between CTF&#946; and NTF of AQP1. <bold>b</bold> The interaction between CFT&#946; and CTF of AQP1. The <italic>lanes</italic> (<italic>1</italic>&#8211;<italic>3</italic>) represent (1) input control of cell lysate, (2) IP with anti-tag antibodies, and (3) IP with normal mouse or rabbit IgG. <bold>c</bold> Cell imaging analysis. Either the CTF&#946; or A&#946; <sub>-42</sub> was expressed as a DsRed-tagged fusion protein, while the full-length AQP1 was expressed as a GFP-tagged fusion protein. They were coexpressed in HEK293 cells. <italic>a</italic> AQP1 with a GFP fluorescence, <italic>b</italic> CTF&#946; with a DsRed fluorescence, <italic>c</italic> merge of <italic>a</italic> and <italic>b</italic> with DAPI, <italic>d</italic> AQP1 with a GFP fluorescence, <italic>e</italic> A&#946;<sub>1-42</sub> with a DsRed fluorescence, and <italic>f</italic> merge of <italic>d</italic> and <italic>e</italic> with DAPI</p>
###xml 965 2103 950 2064 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Molecular interaction of AQP1 and the CTF&#946; of APP. <bold>a</bold>, <bold>b</bold> Immunoprecipitation (IP) analysis. The C-terminal fragment-beta (CTF&#946;) of amyloid precursor protein (APP) was expressed as a Flag-tagged fusion protein, while either the NTF or the CTF of AQP1 was expressed as a Myc-tagged fusion protein. They were coexpressed in HEK293 cells, and processed for pull-down with anti-Flag or anti-Myc antibody, followed by Western blot reciprocally with anti-Myc or anti-Flag antibody. <bold>a</bold> The interaction between CTF&#946; and NTF of AQP1. <bold>b</bold> The interaction between CFT&#946; and CTF of AQP1. The <italic>lanes</italic> (<italic>1</italic>&#8211;<italic>3</italic>) represent (1) input control of cell lysate, (2) IP with anti-tag antibodies, and (3) IP with normal mouse or rabbit IgG. <bold>c</bold> Cell imaging analysis. Either the CTF&#946; or A&#946; <sub>-42</sub> was expressed as a DsRed-tagged fusion protein, while the full-length AQP1 was expressed as a GFP-tagged fusion protein. They were coexpressed in HEK293 cells. <italic>a</italic> AQP1 with a GFP fluorescence, <italic>b</italic> CTF&#946; with a DsRed fluorescence, <italic>c</italic> merge of <italic>a</italic> and <italic>b</italic> with DAPI, <italic>d</italic> AQP1 with a GFP fluorescence, <italic>e</italic> A&#946;<sub>1-42</sub> with a DsRed fluorescence, and <italic>f</italic> merge of <italic>d</italic> and <italic>e</italic> with DAPI</p></caption>
###xml 2103 2103 2064 2064 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_387_Fig6_HTML" id="MO6"/>
###xml 959 2103 944 2064 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="44">Molecular interaction of AQP1 and the CTF&#946; of APP. <bold>a</bold>, <bold>b</bold> Immunoprecipitation (IP) analysis. The C-terminal fragment-beta (CTF&#946;) of amyloid precursor protein (APP) was expressed as a Flag-tagged fusion protein, while either the NTF or the CTF of AQP1 was expressed as a Myc-tagged fusion protein. They were coexpressed in HEK293 cells, and processed for pull-down with anti-Flag or anti-Myc antibody, followed by Western blot reciprocally with anti-Myc or anti-Flag antibody. <bold>a</bold> The interaction between CTF&#946; and NTF of AQP1. <bold>b</bold> The interaction between CFT&#946; and CTF of AQP1. The <italic>lanes</italic> (<italic>1</italic>&#8211;<italic>3</italic>) represent (1) input control of cell lysate, (2) IP with anti-tag antibodies, and (3) IP with normal mouse or rabbit IgG. <bold>c</bold> Cell imaging analysis. Either the CTF&#946; or A&#946; <sub>-42</sub> was expressed as a DsRed-tagged fusion protein, while the full-length AQP1 was expressed as a GFP-tagged fusion protein. They were coexpressed in HEK293 cells. <italic>a</italic> AQP1 with a GFP fluorescence, <italic>b</italic> CTF&#946; with a DsRed fluorescence, <italic>c</italic> merge of <italic>a</italic> and <italic>b</italic> with DAPI, <italic>d</italic> AQP1 with a GFP fluorescence, <italic>e</italic> A&#946;<sub>1-42</sub> with a DsRed fluorescence, and <italic>f</italic> merge of <italic>d</italic> and <italic>e</italic> with DAPI</p></caption><graphic position="anchor" xlink:href="401_2008_387_Fig6_HTML" id="MO6"/></fig>
###xml 1663 1668 <span type="species:ncbi:10090">mouse</span>
###xml 1672 1678 <span type="species:ncbi:9986">rabbit</span>
Finally, the molecular interaction between AQP1 and Abeta was investigated by immunprecipitation of recombinant fusion proteins with distinct epitope tags coexpressed in HEK293 cells, followed by pull down with tag-specific antibodies. Since preliminary experiments suggested that the segment spanning Abeta1-42 alone is not enough to identify the protein-protein interaction owing to its small size (4 kDa) on a conventional Tris-glycine SDS-PAGE gel, we have chosen the CTFbeta of APP, spanning both Abeta and the APP intracellular domain (AICD), expressed as a Flag-tagged fusion protein. Alternatively, either the NTF or the CTF of AQP1 was expressed as a Myc-tagged fusion protein. Pull-down assay showed that the CTFbeta of APP interacts with the NTF of AQP1, but not with the CTF of AQP1, indicating that the molecular interaction is not attributable to an artifact caused by overexpression in HEK293 cells (Fig. 6a, b, upper and lower panels; lane 2).Fig. 6Molecular interaction of AQP1 and the CTFbeta of APP. a, b Immunoprecipitation (IP) analysis. The C-terminal fragment-beta (CTFbeta) of amyloid precursor protein (APP) was expressed as a Flag-tagged fusion protein, while either the NTF or the CTF of AQP1 was expressed as a Myc-tagged fusion protein. They were coexpressed in HEK293 cells, and processed for pull-down with anti-Flag or anti-Myc antibody, followed by Western blot reciprocally with anti-Myc or anti-Flag antibody. a The interaction between CTFbeta and NTF of AQP1. b The interaction between CFTbeta and CTF of AQP1. The lanes (1-3) represent (1) input control of cell lysate, (2) IP with anti-tag antibodies, and (3) IP with normal mouse or rabbit IgG. c Cell imaging analysis. Either the CTFbeta or Abeta -42 was expressed as a DsRed-tagged fusion protein, while the full-length AQP1 was expressed as a GFP-tagged fusion protein. They were coexpressed in HEK293 cells. a AQP1 with a GFP fluorescence, b CTFbeta with a DsRed fluorescence, c merge of a and b with DAPI, d AQP1 with a GFP fluorescence, e Abeta1-42 with a DsRed fluorescence, and f merge of d and e with DAPI
###end p 43
###begin p 44
###xml 54 55 51 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 57 58 54 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 480 481 474 475 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 531 532 522 523 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 586 591 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 593 594 581 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 595 596 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 719 720 707 708 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 772 775 754 757 <sub xmlns:xlink="http://www.w3.org/1999/xlink">-42</sub>
###xml 936 937 918 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 968 969 950 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1005 1006 984 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1016 1017 995 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1022 1023 1001 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1035 1036 1014 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1067 1068 1046 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 1074 1078 1050 1054 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 1110 1111 1086 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">f</italic>
###xml 1121 1122 1097 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1127 1128 1103 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 698 703 <span type="species:ncbi:10090">mouse</span>
###xml 707 713 <span type="species:ncbi:9986">rabbit</span>
Molecular interaction of AQP1 and the CTFbeta of APP. a, b Immunoprecipitation (IP) analysis. The C-terminal fragment-beta (CTFbeta) of amyloid precursor protein (APP) was expressed as a Flag-tagged fusion protein, while either the NTF or the CTF of AQP1 was expressed as a Myc-tagged fusion protein. They were coexpressed in HEK293 cells, and processed for pull-down with anti-Flag or anti-Myc antibody, followed by Western blot reciprocally with anti-Myc or anti-Flag antibody. a The interaction between CTFbeta and NTF of AQP1. b The interaction between CFTbeta and CTF of AQP1. The lanes (1-3) represent (1) input control of cell lysate, (2) IP with anti-tag antibodies, and (3) IP with normal mouse or rabbit IgG. c Cell imaging analysis. Either the CTFbeta or Abeta -42 was expressed as a DsRed-tagged fusion protein, while the full-length AQP1 was expressed as a GFP-tagged fusion protein. They were coexpressed in HEK293 cells. a AQP1 with a GFP fluorescence, b CTFbeta with a DsRed fluorescence, c merge of a and b with DAPI, d AQP1 with a GFP fluorescence, e Abeta1-42 with a DsRed fluorescence, and f merge of d and e with DAPI
###end p 44
###begin p 45
###xml 149 153 143 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 311 315 299 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 631 635 613 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 642 643 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
To obtain additional evidence to support the results of immunoprecipitation analysis, we conducted cell imaging analysis. Either the CTFbeta or Abeta1-42 was expressed as a DsRed-tagged fusion protein, while the full-length AQP1 was expressed as a GFP-tagged fusion protein. The CTFbeta of APP, as well as Abeta1-42, was located chiefly in the cytoplasm, while AQP1 was expressed mainly on the plasma membrane, and none of them were expressed in the nucleus, when overexpressed in HEK 293 cells. A discernible GFP fluorescence was also detected in the cytoplasm, where AQP1 was found to be colocalized with CTFbeta of APP and Abeta1-42 (Fig. 6c, panels a-f).
###end p 45
###begin p 46
###xml 371 372 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 627 628 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 849 850 843 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 1125 1126 1116 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 1138 1144 1129 1135 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;7</label>
###xml 1218 1219 1209 1210 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1307 1308 1298 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1333 1334 1324 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1360 1361 1351 1352 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1452 1453 1443 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1469 1470 1460 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1693 1698 1681 1686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 1711 1714 1696 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1721 1727 1706 1712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 1144 1807 1135 1789 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">Tissue protein overlay analysis with recombinant AQP1 protein as a probe. <bold>a</bold> Western blot of recombinant proteins. The identical blot was labeled sequentially with <italic>a</italic> anti-Xpress antibody or <italic>b</italic> anti-AQP1 antibody H-55. <bold>b</bold> Tissue protein overlay. The tissue sections of the motor cortex of AD were incubated with <italic>a</italic> AQP1-Xpress or <italic>b</italic> LacZ-Xpress. Then, they were processed for immunolabeling with anti-Xpress antibody. After inactivation of the antibodies by autoclaving, the tissue sections were processed for relabeling with anti-A&#946; antibody. Xpress (<italic>brown</italic>) and A&#946; (<italic>red</italic>). The <italic>arrows</italic> indicate an existence of AQP1-binding molecules in the core of A&#946; deposition</p>
###xml 1144 1807 1135 1789 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">Tissue protein overlay analysis with recombinant AQP1 protein as a probe. <bold>a</bold> Western blot of recombinant proteins. The identical blot was labeled sequentially with <italic>a</italic> anti-Xpress antibody or <italic>b</italic> anti-AQP1 antibody H-55. <bold>b</bold> Tissue protein overlay. The tissue sections of the motor cortex of AD were incubated with <italic>a</italic> AQP1-Xpress or <italic>b</italic> LacZ-Xpress. Then, they were processed for immunolabeling with anti-Xpress antibody. After inactivation of the antibodies by autoclaving, the tissue sections were processed for relabeling with anti-A&#946; antibody. Xpress (<italic>brown</italic>) and A&#946; (<italic>red</italic>). The <italic>arrows</italic> indicate an existence of AQP1-binding molecules in the core of A&#946; deposition</p></caption>
###xml 1807 1807 1789 1789 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_387_Fig7_HTML" id="MO7"/>
###xml 1138 1807 1129 1789 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>Fig.&#160;7</label><caption><p textid="47">Tissue protein overlay analysis with recombinant AQP1 protein as a probe. <bold>a</bold> Western blot of recombinant proteins. The identical blot was labeled sequentially with <italic>a</italic> anti-Xpress antibody or <italic>b</italic> anti-AQP1 antibody H-55. <bold>b</bold> Tissue protein overlay. The tissue sections of the motor cortex of AD were incubated with <italic>a</italic> AQP1-Xpress or <italic>b</italic> LacZ-Xpress. Then, they were processed for immunolabeling with anti-Xpress antibody. After inactivation of the antibodies by autoclaving, the tissue sections were processed for relabeling with anti-A&#946; antibody. Xpress (<italic>brown</italic>) and A&#946; (<italic>red</italic>). The <italic>arrows</italic> indicate an existence of AQP1-binding molecules in the core of A&#946; deposition</p></caption><graphic position="anchor" xlink:href="401_2008_387_Fig7_HTML" id="MO7"/></fig>
###xml 134 139 <span type="species:ncbi:9606">human</span>
To determine the in vivo molecular interaction between AQP1 and Abeta, we performed tissue protein overlay analysis using recombinant human AQP1 protein spanning the entire ORF tagged with Xpress (AQP1-Xpress) that enables us to identify the expression of AQP1-binding proteins in situ. This probe was recognized by both anti-AQP1 antibody and anti-Xpress antibody (Fig. 7a, panels a and b; lane 2). By tissue protein overlay, the AQP1-Xpress probe did not decorate the entire surface of Abeta-immunoreactive plaques, but the core of the plaques often expressed a nodular or irregular-shaped AQP1-Xpress-immunoreactivity (Fig. 7b, panel a). The AQP1-Xpress probe also reacted intensely with many neurons, neuropil, and microglia in AD brains, suggesting that these cells and constituents might express the molecules with AQP1-binding epitopes (Fig. 7b, panel a). The AQP1-Xpress probe did not label multipolar fibrillary astrocytes. In contrast, the LacZ-Xpress probe did not react with neurons, microglia, astrocytes, or Abeta plaques, excluding non-specific interaction via the Xpress epitope of recombinant proteins (Fig. 7b, panel b).Fig. 7Tissue protein overlay analysis with recombinant AQP1 protein as a probe. a Western blot of recombinant proteins. The identical blot was labeled sequentially with a anti-Xpress antibody or b anti-AQP1 antibody H-55. b Tissue protein overlay. The tissue sections of the motor cortex of AD were incubated with a AQP1-Xpress or b LacZ-Xpress. Then, they were processed for immunolabeling with anti-Xpress antibody. After inactivation of the antibodies by autoclaving, the tissue sections were processed for relabeling with anti-Abeta antibody. Xpress (brown) and Abeta (red). The arrows indicate an existence of AQP1-binding molecules in the core of Abeta deposition
###end p 46
###begin p 47
###xml 74 75 74 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 216 217 216 217 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 308 309 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 325 326 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 549 554 546 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brown</italic>
###xml 567 570 561 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 577 583 571 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
Tissue protein overlay analysis with recombinant AQP1 protein as a probe. a Western blot of recombinant proteins. The identical blot was labeled sequentially with a anti-Xpress antibody or b anti-AQP1 antibody H-55. b Tissue protein overlay. The tissue sections of the motor cortex of AD were incubated with a AQP1-Xpress or b LacZ-Xpress. Then, they were processed for immunolabeling with anti-Xpress antibody. After inactivation of the antibodies by autoclaving, the tissue sections were processed for relabeling with anti-Abeta antibody. Xpress (brown) and Abeta (red). The arrows indicate an existence of AQP1-binding molecules in the core of Abeta deposition
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 910 912 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 914 916 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">55</xref>
###xml 1886 1888 1859 1861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 2143 2145 2116 2118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
In the present study, we investigated the relationship between Abeta deposition and astrocytic AQP1 expression in the motor cortex and hippocampus of 11 AD patients and 16 age-matched non-AD cases. We found that AQP1 was expressed exclusively in a subpopulation of multipolar fibrillary astrocytes in all cases. The great majority of AQP1-expressing astrocytes were located either on the top of or in close proximity to Abeta plaques in AD brains but not in non-AD cases, whereas AQP1-expressing astrocytes independent of Abeta deposition were found predominantly in non-AD brains. By tissue protein overlay analysis, AQP1-Xpress-immunoreactivities, reflecting the existence of the molecules with AQP1-binding epitopes, were located in the core of Abeta plaques in AD brains. A number of previous studies showed that astrocytes, keeping in touch with Abeta plaques, are activated by Abeta itself in AD brains [37, 55]. In line with the previous observations, we showed that AQP1-expressing multipolar fibrillary astrocytes are closely associated with Abeta deposition in AD brains. These observations suggest the hypothesis that Abeta deposition might cause abnormal brain water homeostasis by interfering with astrocytic water channel function. The present study included solely AD brains classified into the most advanced stage of the disease. To evaluate the hypothesis described above, it is important to investigate AQP1 expression in AD brains at early stages with minimal deposition or diffuse plaques of Abeta. Importantly, a recent study using Western blot and immunohistochemistry showed that the levels of AQP1 protein expression are significantly elevated in the frontal cerebral cortex of AD at the Braak's stage II, where reactive astrocytes similar to multipolar fibrillary astrocytes observed in the present study express a cell-surface punctuate AQP1 immunoreactivity [43]. In contrast, no differences are found in AQP1 protein levels between the stages V-VI of AD and the age-matched control cases, suggesting the possibility that upregulated expression of AQP1 on astrocytes in AD brains is a disease stage-dependent event [43].
###end p 49
###begin p 50
###xml 485 486 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 488 490 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 755 757 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 798 802 783 787 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 1132 1134 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1257 1259 1242 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 1399 1400 1381 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1402 1404 1384 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">52</xref>
To obtain a deeper insight into our in vivo observations of close association of AQP1-expressiong astrocytes with Abeta, we studied the molecular interaction between AQP1 and Abeta in a transient expression system of HEK293 cells in vitro. By the pull-down assay, the CTFbeta of APP interacts with the N-terminal half (amino acid residues 2-132; NTF) of AQP1 spanning the transmembrane helices H1, H2, and H3, which contains one of two NPA motifs pivotal for water transport function [2, 32]. A recent study indicated that the amino acid residues composed of Phe 58, His 182, Cys 191, and Arg 197 are involved in constituting the constriction region of water channel, while both His 76 and Val 155 act as a valve by dynamically blocking water permeation [49]. AQP1, along with the CTFbeta and Abeta1-42, were colocalized on the cell-surface membrane and in the cytoplasm, when they were coexpressed in cultured cells. Although the primary site of AQP1 expression is the cell-surface membrane, the intracellular location of AQP1 has been reported previously. AQP1 integrates into the ER membrane, when overexpressed in HEK293 cells [11]. Secretin induces a redistribution of AQP1 protein from intracellular vesicles to the plasma membrane in cholangiocytes [33]. Importantly, both APP and AQP1 constitute transmembrane proteins, and Abeta and AQP1 are enriched in lipid rafts of the plasma membrane [7, 52], raising the possibility of a direct protein-protein interaction between Abeta and AQP1 at cell-to-cell contact interfaces in situ.
###end p 50
###begin p 51
###xml 362 363 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 964 965 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 1094 1095 1070 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 1098 1104 1074 1080 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;8</label>
###xml 1415 1417 1388 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 1664 1665 1628 1629 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1752 1753 1713 1714 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1104 1865 1080 1823 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">Working models of the molecular interaction between AQP1 and A&#946;. AQP1 is composed of a homotetramer of 28-kDa subunits. Each monomeric subunit contains six transmembrane helices (H1&#8211;H6) with two hemipores with an Asparagine&#8211;Proline&#8211;Alanine (NPA) motif, which fold to form a water channel (see the reference [<xref ref-type="bibr" rid="CR32">32</xref>]). Pull-down assay suggested that the CTF&#946; of APP, composed of A&#946; and AICD, interacts with the N-terminal half of AQP1 spanning H1, H2, and H3. Two different working models could be proposed for the molecular interaction of AQP1 and A&#946;; <bold>a</bold> astrocytic AQP1 could interact with extracellular deposition of fibrillary A&#946;, and <bold>b</bold> astrocytic AQP1 could interact with the A&#946; and/or AICD transmembrane/intracellular segment of endogenous APP</p>
###xml 1104 1865 1080 1823 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52">Working models of the molecular interaction between AQP1 and A&#946;. AQP1 is composed of a homotetramer of 28-kDa subunits. Each monomeric subunit contains six transmembrane helices (H1&#8211;H6) with two hemipores with an Asparagine&#8211;Proline&#8211;Alanine (NPA) motif, which fold to form a water channel (see the reference [<xref ref-type="bibr" rid="CR32">32</xref>]). Pull-down assay suggested that the CTF&#946; of APP, composed of A&#946; and AICD, interacts with the N-terminal half of AQP1 spanning H1, H2, and H3. Two different working models could be proposed for the molecular interaction of AQP1 and A&#946;; <bold>a</bold> astrocytic AQP1 could interact with extracellular deposition of fibrillary A&#946;, and <bold>b</bold> astrocytic AQP1 could interact with the A&#946; and/or AICD transmembrane/intracellular segment of endogenous APP</p></caption>
###xml 1865 1865 1823 1823 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_387_Fig8_HTML" id="MO8"/>
###xml 1098 1865 1074 1823 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig8"><label>Fig.&#160;8</label><caption><p textid="52">Working models of the molecular interaction between AQP1 and A&#946;. AQP1 is composed of a homotetramer of 28-kDa subunits. Each monomeric subunit contains six transmembrane helices (H1&#8211;H6) with two hemipores with an Asparagine&#8211;Proline&#8211;Alanine (NPA) motif, which fold to form a water channel (see the reference [<xref ref-type="bibr" rid="CR32">32</xref>]). Pull-down assay suggested that the CTF&#946; of APP, composed of A&#946; and AICD, interacts with the N-terminal half of AQP1 spanning H1, H2, and H3. Two different working models could be proposed for the molecular interaction of AQP1 and A&#946;; <bold>a</bold> astrocytic AQP1 could interact with extracellular deposition of fibrillary A&#946;, and <bold>b</bold> astrocytic AQP1 could interact with the A&#946; and/or AICD transmembrane/intracellular segment of endogenous APP</p></caption><graphic position="anchor" xlink:href="401_2008_387_Fig8_HTML" id="MO8"/></fig>
However, it should be kept in mind that the binding of AQP1 to Abeta in vitro does not always precisely reflect the in vivo situation of the interaction between AQP1-expressing astrocytes and Abeta. Importantly, both reactive astrocytes and activated microglia express scavenger receptors that mediate the clearance of extracellularly-deposited fibrillar Abeta [1]. Therefore, it is meaningful to study in the next step the molecular interaction of AQP1 and fibrillar Abeta, and its physiological interference with water transport in an astrocyte culture model in vitro. Although the present study, in the absence of high-resolution immunoelectron microscopic analysis dose not provide definitive evidence to show the direct interaction between Abeta and AQP1 in vivo, we could currently propose two different working models of the molecular interaction of AQP1 and Abeta; (1) astrocytic AQP1 could interact with extracellular deposition of fibrillary Abeta (Fig. 8a) and (2) astrocytic AQP1 could interact with the Abeta and/or AICD transmembrane/intracellular segment of endogenous APP (Fig. 8b).Fig. 8Working models of the molecular interaction between AQP1 and Abeta. AQP1 is composed of a homotetramer of 28-kDa subunits. Each monomeric subunit contains six transmembrane helices (H1-H6) with two hemipores with an Asparagine-Proline-Alanine (NPA) motif, which fold to form a water channel (see the reference [32]). Pull-down assay suggested that the CTFbeta of APP, composed of Abeta and AICD, interacts with the N-terminal half of AQP1 spanning H1, H2, and H3. Two different working models could be proposed for the molecular interaction of AQP1 and Abeta; a astrocytic AQP1 could interact with extracellular deposition of fibrillary Abeta, and b astrocytic AQP1 could interact with the Abeta and/or AICD transmembrane/intracellular segment of endogenous APP
###end p 51
###begin p 52
###xml 311 313 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 560 561 548 549 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 648 649 633 634 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
Working models of the molecular interaction between AQP1 and Abeta. AQP1 is composed of a homotetramer of 28-kDa subunits. Each monomeric subunit contains six transmembrane helices (H1-H6) with two hemipores with an Asparagine-Proline-Alanine (NPA) motif, which fold to form a water channel (see the reference [32]). Pull-down assay suggested that the CTFbeta of APP, composed of Abeta and AICD, interacts with the N-terminal half of AQP1 spanning H1, H2, and H3. Two different working models could be proposed for the molecular interaction of AQP1 and Abeta; a astrocytic AQP1 could interact with extracellular deposition of fibrillary Abeta, and b astrocytic AQP1 could interact with the Abeta and/or AICD transmembrane/intracellular segment of endogenous APP
###end p 52
###begin p 53
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">53</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">56</xref>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">50</xref>
###xml 1038 1039 1038 1039 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 1061 1063 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1172 1174 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 1688 1690 1688 1690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 894 897 <span type="species:ncbi:10116">rat</span>
###xml 1153 1158 <span type="species:ncbi:10090">mouse</span>
###xml 1371 1376 <span type="species:ncbi:9606">human</span>
###xml 1661 1664 <span type="species:ncbi:10116">rat</span>
Regulatory mechanisms underlying AQP1 expression are highly complex. Systemic hyponatremia elevates the levels of expression of AQP1 on choroid plexus epithelial cells [35]. Thyroid transcription factor-1 (TTF1), expressed in choroids plexus epithelium, facilitates CSF production by enhancing AQP1 gene expression [25]. Hypertonic stress induces the expression of AQP1 in rodent renal medullary cells by activating extracellular signal-regulated kinase (ERK), p38 MAP kinase, and c-Jun N-terminal kinase (JNK), all of which regulate a hypertonicity-responsive element (HRE) located in the AQP1 promoter [53]. Acetazolamide inhibits the osmotic water permeability by reducing AQP1 protein expression [56]. Treatment with corticosteroids increases the levels of AQP1 protein expression in the capillary endothelium of the peritoneal membrane and the lung [26, 50]. AQP1 expression is induced in rat gliosarcoma cells by exposure to hypoxia, dexamethasone, and PDGF, and by incubating the cells in hypertonic culture media containing NaCl, d-glucose or fructose [17]. Treatment with proteasome inhibitors elevates the levels of AQP1 protein expression in mouse fibroblasts [29]. All of these observations suggest that distinct promoter elements are activated in response to osmotic and non-osmotic stimuli in different cell types. We found that AQP1 expression in cultured human astrocytes is upregulated markedly by hypertonic sodium chloride, modestly by MG-132, and downregulated by PMA, an activator of protein kinase C (PKC). It is worthy to note that tetradecanoylphorbol 13-acetate (TPA), another activator of PKC, induces a rapid decrease in AQP4 mRNA in rat astrocytes in culture [38].
###end p 53
###begin p 54
###xml 185 186 185 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 190 191 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 860 861 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 412 415 <span type="species:ncbi:10116">rat</span>
###xml 494 499 <span type="species:ncbi:9606">human</span>
###xml 1128 1133 <span type="species:ncbi:9606">human</span>
The pathophysiological role of AQP1-expressing multipolar fibrillary astrocytes in AD brains remains unknown. Increasing evidence indicate that AQP1 acts as a gas transporter, such as O2, CO2, and NO [6, 13, 18]. AQP1, by transporting NO out of endothelial cells and into vascular smooth muscle cells, plays a pivotal role in endothelium-dependent vasorelaxation [18]. AQP1 expression is markedly upregulated in rat lungs by hypoxia [13]. AQP1 is required for hypoxia-inducible angiogenesis in human retinal vascular endothelial cells [23]. We showed previously that AQP1-expressing astrocytes accumulate in ischemic lesions of cerebral infarction and active demyelinating lesions of MS [47]. Because the production of NO and reactive nitrogen species (RNS), as well as reactive oxygen species (ROS), is markedly enhanced in the brains of ischemia, MS and AD [3], the possibility exists that AQP1-expressing astrocytes with a great migratory capacity [54] act as a scavenger of RNS and ROS by patrolling the cortex of AD. However, treatment with SNP and hydrogen peroxide did not affect the levels of AQP1 protein expression in human astrocytes in culture, suggesting that these stimuli do not directly upregulate AQP1 expression in astrocytes.
###end p 54
###begin p 55
###xml 119 123 116 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 806 807 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 809 811 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1016 1018 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 1185 1187 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 1304 1306 1280 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1583 1585 1559 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 1722 1726 1692 1696 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 2547 2548 2505 2506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 64 69 <span type="species:ncbi:9606">human</span>
###xml 1021 1026 <span type="species:ncbi:9606">Human</span>
We found that the levels of AQP1 protein expression on cultured human astrocytes were not affected by exposure to Abeta1-42 peptide at least within a 48 h-observation period, although we observed a drastic change in morphology of astrocytes, exhibiting the morphology with ruffled cell-surface membranes (Supplementary Fig. 4). The molecular basis for this change remains unknown. Even though Abeta desposition does not act as a potent inducer for AQP1 expression in cortical astrocytes in AD brains, the close association of AQP1 with Abeta suggests that extensive Abeta deposition could cause abnormal brain water homeostasis by interfering with astrocytic water channel function. Supporting this view, previous clinical studies showed that brain ion and water homeostasis is profoundly disturbed in AD [5, 20]. Recent studies have indicated that intracerebral accumulation of not only Abeta oligomers but also that of the APP intracellular domain (AICD) affects the gene expression involved in neuronal survival [36]. Human astrocytes produce Abeta in response to TGFbeta, suggesting that astrocytes might coexpress Abeta, along with AQP1, when activated by cytokines in AD brains [30]. The great majority of APP holoprotein is located in intracellular membranous compartments in cultured astrocytes [15]. AQP1 is produced initially as a precursor protein with four transmembrane segment-spanning topology at the ER membrane, and following topological reorientation it is processed to form a mature protein with six transmembrane segment-spanning topology at the plasma mambrane [31]. After overexpression of the transgenes without signal peptide sequences in HEK 293 cells, the CTFbeta of APP, as well as that of Abeta1-42, was located chiefly in the cytoplasm, while AQP1 was expressed mainly on the plasma membrane and less abundantly in the cytoplasm. Although the overexpression experiments in HEK293 cells do not precisely reflect the physiological situation, a discernible colocalization was detected in the cytoplasm, not excluding the interaction in intracellular membranous compartments. The pull-down assay showed that the CTFbeta, composed of both Abeta and AICD, interacts directly with the NTF of AQP1, although these observations did not specify the AQP1-interacting domain of APP, either Abeta or AICD, or both. Therefore, the possible scenario could be raised that astrocytic Abeta and/or AICD segment of endogenous APP interacts with AQP1 either on the plasma membrane or at specific intracellular membrane compartments (Fig. 8b). In addition, the hypothetical view could be proposed that Abeta and AICD, by binding to AQP1, not only affect water permeability, but also modulate signaling pathways in astrocytes essential for supporting neuronal survival in the brains of AD.
###end p 55
###begin p 56
In conclusion, AQP1-expressing fibrillary astrocytes, which represent a unique subset of astrocytes, might have a close association with Abeta in the brains of advanced stages of AD, although there exists no definitive evidence to show the direct contact. However, these observations suggest the working hypothesis that Abeta deposition could cause abnormal brain water homeostasis by interfering with astrocytic water channel function. Further studies, including the immunohistochemical analysis of various disease stages, high-resolution morphological analysis, and cell physiological analysis, are required to evaluate this hypothesis.
###end p 56
###begin title 57
Electronic supplementary material
###end title 57
###begin p 58
Below is the link to the electronic supplementary material.
###end p 58
###begin p 59
###xml 112 119 <span type="species:ncbi:9606">patient</span>
Supplementary Fig. 1. Choroid plexus epithelial cells express AQP1. The tissue sections of the hippocampus of a patient with AD were processed for double-labeling immunohistochemistry with anti-AQP1 antibody (H-55, brown) and anti-Abeta antibody (12B2, red) (PPT 1447 kb)
###end p 59
###begin p 60
###xml 104 111 <span type="species:ncbi:9606">patient</span>
Supplementary Fig. 2. Perivascular astrocytes express AQP4. The tissue sections of the hippocampus of a patient with AD were processed for double-labeling immunohistochemistry with anti-AQP4 antibody (H-80, brown) and anti-Abeta antibody (12B2, red) (PPT 1065 kb)
###end p 60
###begin p 61
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 111 116 <span type="species:ncbi:9606">human</span>
Supplementary Fig. 3. Real-time RT-PCR analysis of AQP1 mRNA expression in cultured human astrocytes. Cultured human astrocytes were untreated (CNT) or exposed for 48 hours to 100 mM NaCl or 100 nM phorbol 12-myristate 13-acetate (PMA). They were then processed for real-time RT-PCR analysis by using the AQP1-specific primer set. The levels of AQP1 mRNA were standardized against those of the glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene detected in the identical cDNA samples (PPT 49 kb)
###end p 61
###begin p 62
###xml 78 82 75 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 200 204 193 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-40</sub>
###xml 233 237 222 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1-42</sub>
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 101 106 <span type="species:ncbi:9606">human</span>
Supplementary Fig. 4. Morphology of cultured human astrocytes exposed to Abeta1-42 peptide. Cultured human astrocytes were exposed for 48 hours to (a) the vehicle (dimethylsulfoxide), (b) 10 muM Abeta1-40 peptide, or (c) 10 muM Abeta1-42 peptide. Phase-contrast photomicrographs. Also see the footnote of Fig. 5 (PPT 3075 kb)
###end p 62
###begin p 63
All autopsied brain samples were obtained from Research Resource Network (RRN), Japan. This work was supported by grants to JIS from Research on Psychiatric and Neurological Diseases and Mental Health, the Ministry of Health, Labour and Welfare of Japan (H17-kokoro-020), Research on Health Sciences Focusing on Drug Innovation, the Japan Health Sciences Foundation (KH21101), the Grant-in-Aid for Scientific Research, the Ministry of Education, Culture, Sports, Science and Technology, Japan (B18300118), and the Nakatomi Foundation.
###end p 63
###begin p 64
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
###xml 115 119 <span type="species:ncbi:10116">rats</span>
Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid
###end article-title 66
###begin article-title 67
The molecular basis of water transport in the brain
###end article-title 67
###begin article-title 68
Reactive oxygen and nitrogen species in Alzheimer's disease
###end article-title 68
###begin article-title 69
###xml 42 47 <span type="species:ncbi:9606">human</span>
Aquaporin 1 and aquaporin 4 expression in human brain after subarachnoid hemorrhage and in peritumoral tissue
###end article-title 69
###begin article-title 70
MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease
###end article-title 70
###begin article-title 71
###xml 74 79 <span type="species:ncbi:9606">human</span>
Aquaporin-1 and HCO3-Cl- transporter-mediated transport of CO2 across the human erythrocyte membrane
###end article-title 71
###begin article-title 72
Quantitative profiling of the detergent-resistant membrane proteome of iota-b toxin induced vero cells
###end article-title 72
###begin article-title 73
Ion channel function of aquaporin-1 natively expressed in choroid plexus
###end article-title 73
###begin article-title 74
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
###end article-title 74
###begin article-title 75
A novel tripartite motif involved in aquaporin topogenesis, monomer folding and tetramerization
###end article-title 75
###begin article-title 76
Evidence that the transmembrane biogenesis of aquaporin 1 is cotranslational in intact mammalian cells
###end article-title 76
###begin article-title 77
###xml 62 65 <span type="species:ncbi:10116">rat</span>
Induction of aquaporin 1 but not aquaporin 4 messenger RNA in rat primary brain microvessel endothelial cells in culture
###end article-title 77
###begin article-title 78
Development of cytosolic hypoxia and hypoxia-inducible factor stabilization are facilitated by aquaporin-1 expression
###end article-title 78
###begin article-title 79
###xml 64 69 <span type="species:ncbi:9606">human</span>
Localization of aquaporin-1 water channel in glial cells of the human peripheral nervous system
###end article-title 79
###begin article-title 80
Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion
###end article-title 80
###begin article-title 81
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide
###end article-title 81
###begin article-title 82
Regulation and function of aquaporin-1 in glioma cells
###end article-title 82
###begin article-title 83
Novel role of AQP-1 in NO-dependent vasorelaxation
###end article-title 83
###begin article-title 84
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth
###end article-title 84
###begin article-title 85
###xml 50 62 <span type="species:ncbi:9606">participants</span>
Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss
###end article-title 85
###begin article-title 86
Increased migration and metastatic potential of tumor cells expressing aquaporin water channels
###end article-title 86
###begin article-title 87
Plasma membrane aquaporin activity can affect the rate of apoptosis but is inhibited after apoptotic volume decrease
###end article-title 87
###begin article-title 88
###xml 62 67 <span type="species:ncbi:9606">human</span>
Aquaporin 1 is required for hypoxia-inducible angiogenesis in human retinal vascular endothelial cells
###end article-title 88
###begin article-title 89
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
Identification and characterization of an aquaporin 1 immunoreactive amacrine-type cell of the mouse retina
###end article-title 89
###begin article-title 90
Thyroid transcription factor-1 faciliattes cerebrospinal fluid formation by regulating aquaporin-1 synthesis in the brain
###end article-title 90
###begin article-title 91
###xml 101 104 <span type="species:ncbi:10116">rat</span>
Aquaporin-1 water channel protein in lung. Ontogeny, steroid-induced expression, and distribution in rat
###end article-title 91
###begin article-title 92
Defective urinary concentrating ability due to a complete deficiency of aquaporin-1
###end article-title 92
###begin article-title 93
###xml 62 68 <span type="species:ncbi:9606">humans</span>
Decreased pulmonary vascular permeability in aquaporin-1-null humans
###end article-title 93
###begin article-title 94
Altered ubiquitination and stability of aquaporin-1 in hypertonic stress
###end article-title 94
###begin article-title 95
###xml 90 105 <span type="species:ncbi:10090">transgenic mice</span>
Transforming growth factor-beta1 potentiates amyloid-beta generation in astrocytes and in transgenic mice
###end article-title 95
###begin article-title 96
Reorientation of aquaporin-1 topology during maturation in the endoplasmic reticulum
###end article-title 96
###begin article-title 97
###xml 28 33 <span type="species:ncbi:9606">human</span>
AQP1 expression analysis in human diseases: implications for proteomic characterization
###end article-title 97
###begin article-title 98
###xml 45 48 <span type="species:ncbi:10116">rat</span>
Secretin promotes osmotic water transport in rat cholangiocytes by increasing aquaporin-1 water channels in plasma membrane
###end article-title 98
###begin article-title 99
The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.
###end article-title 99
###begin article-title 100
Increased aquaporin-1 expression in choroid plexus epithelium after systemic hyponatremia
###end article-title 100
###begin article-title 101
Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD)
###end article-title 101
###begin article-title 102
Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease
###end article-title 102
###begin article-title 103
###xml 57 60 <span type="species:ncbi:10116">rat</span>
Effect of TPA on aquaporin 4 mRNA expression in cultured rat astrocytes
###end article-title 103
###begin article-title 104
Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia
###end article-title 104
###begin article-title 105
###xml 47 52 <span type="species:ncbi:9606">human</span>
Expression of the aquaporin-1 water channel in human glial tumors
###end article-title 105
###begin article-title 106
###xml 68 72 <span type="species:ncbi:10090">mice</span>
Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1
###end article-title 106
###begin article-title 107
Aquaporin expression in the cerebral cortex is increased at early stages of Alzheimer disease
###end article-title 107
###begin article-title 108
###xml 102 108 <span type="species:ncbi:9913">bovine</span>
###xml 144 150 <span type="species:ncbi:9913">bovine</span>
###xml 155 170 <span type="species:ncbi:10090">transgenic mice</span>
Increased expression of water channel aquaporin 1 and aquaporin 4 in Creutzfeldt-Jakob disease and in bovine spongiform encephalopathy-infected bovine-PrP transgenic mice
###end article-title 108
###begin article-title 109
###xml 50 55 <span type="species:ncbi:9606">human</span>
Increased aquaporin 1 water channel expression in human brain tumours
###end article-title 109
###begin article-title 110
Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption
###end article-title 110
###begin article-title 111
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human astrocytes express aquaporin-1 and aquaporin-4 in vitro and in vivo
###end article-title 111
###begin article-title 112
Anatomical and functional analysis of aquaporin 1, a water channel in primary afferent neurons
###end article-title 112
###begin article-title 113
###xml 95 98 <span type="species:ncbi:10116">rat</span>
Corticosteroids induce expression of aquaporin-1 and increase transcellular water transport in rat epithelium
###end article-title 113
###begin article-title 114
Astrocytes co-express aquaporin-1, -4, and vascular endothelial growth factor in brain edema tissue associated with brain contusion
###end article-title 114
###begin article-title 115
Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins
###end article-title 115
###begin article-title 116
Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity-responsive element in the AQP1 gene
###end article-title 116
###begin article-title 117
More than just water channels: unexpected cellular roles of aquaporins
###end article-title 117
###begin article-title 118
Spatial relationships between astrocytes and classical plaque components
###end article-title 118
###begin article-title 119
Acetazolamide inhibits aquaporin-1 protein expression and angiogenesis
###end article-title 119
###begin p 120
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 120
###begin p 121
The online version of this article (doi:10.1007/s00401-008-0387-x) contains supplementary material, which is available to authorized users.
###end p 121

